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5For my parents.
‘Donner à nos enfants le désir de savoir, éveiller leur curiosité.’
‘Convey to our children the desire for knowledge, awaken their curiosity.’
- Albert Barillé, creator of the Once Upon a Time...Life cartoon -
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ABSTRACT
Atherosclerosis is the underlying cause of myocardial infarction and stroke, the 
leading causes of death worldwide. It is a complex multifactorial disease closely 
linked with obesity, type II diabetes, and metabolic syndrome and, together, these 
conditions comprise the global epidemic of metabolic disorders that are becoming 
more and more prevalent, affecting adults and children alike. 
Atherosclerosis affects the large arteries that gradully loose their normal structure 
and function via a degenerative process involving lipid accumulation and chronic 
inflammation in the arterial wall. The lipid accumulation is driven by high circulating 
levels of cholesterol-carrying low density lipoproteins that become trapped and 
modified in the arterial wall. This causes an inflammatory reaction characterized 
by abundant immune cell infiltrates, mainly monocyte-derived macrophages. The 
macrophages scavenge large amounts of lipids and become activated to secrete a 
host of proinflammatory mediators and matrix-degrading enzymes that drive the 
progression of the disease. These processes result in the focal development of fatty 
lesions or ‘plaques’ along the arteries. Over time, more complex lesions develop as 
a result of inflammatory and fibrotic responses, matrix remodeling, calcification, 
cholesterol crystallization, neovessel formation, and microhemorrhages. Ultimately, 
the plaques may rupture, causing thrombosis and acute complications. 
Although inflammation is recognized as a major driving force in atherosclerotic 
lesion development, the mechanisms triggering and maintaining the arterial 
wall inflammation remain incompletely understood. The aim of this thesis was 
to study the role of a key innate immune signaling pathway, the inflammasome, 
in atherosclerosis. The inflammasomes are large cytoplasmic signaling complexes 
that trigger the proteolytic maturation and secretion of two proinflammatory and 
proatherogenic cytokines, interleukin(IL)-1? and -18. The inflammasome pathway 
can be triggered by microbial components or by sterile endogenous danger signals 
that elicit the activation of cytoplasmic sensor molecules from the NLR (nucleotide-
binding domain and leucine-rich repeat containing) or PYHIN (pyrin and HIN 
domain containing) families. Despite the established roles of IL-1? and -18 in 
driving atherosclerotic lesion development, the triggers of inflammasome activation 
in atherosclerotic plaques remained unknown. 
Macrophages are the prototypical inflammasome pathway-expressing cells, 
and thus cultured human macrophages were utilized to identify and characterize 
atherosclerosis-associated triggers of the inflammasome pathway. Cholesterol crystals 
and acidic environment were both found to trigger a strong inflammatory response 
via the activation of NLRP3 inflammasome and secretion of IL-1??and IL-18. 
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Cholesterol crystals are a hallmark of atherosclerotic lesions, yet they have been 
considered an inert material that merely acts as a sink for excess free cholesterol in 
the arterial wall. These new data suggested, however, that cholesterol crystals act as 
a potent sterile danger signal that may directly link pathological lipid accumulation 
and inflammation in the lesions. Local extracellular acidosis arises in the growing 
plaque due to the hindered diffusion of oxygen and the highly active glycolytic 
metabolism of macrophages. Acidic environment not only triggered the NLRP3 
inflammasome, but even a very mild acidification from the physiological pH of 7.4 to 
7.0 was sufficient to greatly amplify the IL-1? response to other NLRP3 activators, 
including cholesterol crystals.
Having showed that the atherosclerotic lesions harbour potent activators of 
the inflammasome pathway, we further analyzed the expression of this pathway 
in atherosclerotic human coronary specimens obtained from 10 explanted hearts. 
For this purpose, we utilized a quantitative PCR array targeting 88 inflammasome 
pathway-related molecules. Significant upregulation of 12 target genes was found 
in advanced coronary plaques compared to early lesions from the same coronary 
trees, including many of the very core components of the inflammasome pathway. 
Moreover, p38? mitogen-activated protein kinase (MAPK), a poorly characterized 
isoform of the stress- and cytokine-activated p38 MAPK family, was consistently 
upregulated in advanced coronary plaques. Immunohistochemical stainings of human 
coronary lesions showed strong expression of NLRP3 inflammasome components 
and p38??MAPK in macrophages surrounding the cholesterol crystal-rich lipid core. 
Furthermore, the p38? MAPK was activated in cultured human macrophages upon 
NLRP3 inflammasome activation by cholesterol crystals and extracellular ATP, and 
required for NLRP3-mediated IL-1? secretion. 
Taken together, the data presented in this thesis propose novel inflammasome-
mediated mechanisms that may trigger sterile inflammation in atherosclerotic lesions 
and thus drive lesion progression.
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TIIVISTELMÄ
Tässä väitöskirjatyössä tutkittiin tulehdusreaktioiden merkitystä valtimon 
rasvakovettumataudin eli ateroskleroosin kehittymisessä. Ateroskleroosissa 
valtimoverisuonien seinämään kertyy sekä veren lipoproteiini-hiukkasten kantamaa 
kolesterolia että immuunipuolustuksen syöjäsoluja eli makrofageja. Makrofagit 
yrittävät poistaa liiallista kolesterolia, mutta juuttuvat lopulta rasvarakkuloiden 
täyttäminä valtimon seinämään ja laukaisevat ateroskleroosin etenemistä edistävän 
kroonisen tulehdusreaktion. Sen seurauksena rasva-aineiden ja tulehdussolujen 
muodostamat kertymät kehittyvät vähitellen monimuotoisiksi valtimoa ahtauttaviksi 
plakeiksi, jotka voivat revetessään aiheuttaa aivo- tai sydäninfarktin. 
Inflammasomi on makrofageista löydetty tulehdussignalointireitti, jonka aktivaatio 
laukaisee voimakkaan tulehdusreaktion käynnistämällä tulehdusvälittäjäaine 
interleukiini (IL)-1?:n erityksen. Ateroskleroosin hiirimalleissa geneettinen IL-
1?-puutos vähentää huomattavasti plakkien kasvua, ja IL-1?:n määrä lisääntyy 
myös ihmisen valtimon seinämässä plakkien kehittyessä. Plakkien inflammasomi-
aktivaatiota ja IL-1?-eritystä laukaisevia tekijöitä ei kuitenkaan aiemmin tunnettu 
ja väitöskirjatutkimuksen tavoitteena oli tunnistaa tällaisia tekijöitä. Tutkimus osoitti, 
että plakeissa yleisesti esiintyvät kolesterolikiteet sekä plakin kehittymiseen liittyvä 
kudosnesteen paikallinen happamoituminen laukaisevat makrofageissa voimakkaan 
inflammasomi-välitteisen tulehdusvasteen IL-1?-erityksen kautta. Elimistön 
immuunipuolustus kykenee siis tunnistamaan kyseiset taudinkehitykseen liittyvät 
muutokset vaarasignaaleiksi ja reagoimaan niihin käynnistämällä tulehdusreaktion.
Kolesterolikiteitä on vuosikymmenien ajan pidetty ateroskleroosin kehityksen 
kannalta merkityksettöminä sivutuotteina. Tutkimuksen tulokset haastoivat tämän 
käsityksen osoittamalla, että kolesterolikiteet ovat aktiivinen tekijä ateroskleroosin 
kehittymisessä ja voivat selittää häiriintyneen rasva-aineenvaihdunnan ja valtimon 
seinämän tulehduksen välistä yhteyttä. Lisäksi tutkimuksessa havaittiin, että jo hyvin 
lievä solunulkoinen happamoituminen voimistaa merkittävästi kolesterolikiteiden 
aiheuttamaa tulehdusvastetta makrofageissa, kun nämä ärsykkeet annetaan soluille 
samanaikaisesti.
Väitöskirjatyössä inflammasomi-reitin toiminnallisuutta tutkittiin myös sydämen 
sepelvaltimonäytteissä laajan geeni-ilmentymisanalyysin ja vasta-ainevärjäysten 
avulla. Tulokset osoittivat, että kaikki inflammasomi-reitin keskeisimmät 
komponentit ilmentyvät sepelvaltimon seinämän makrofageissa ja useat niistä 
lisääntyvät merkittävästi ateroskleroottisten plakkien kehittymisen myötä. Geeni-
ilmentymisanalyysissa havaittiin myös erään tulehdusta säätelevän molekyylin, 
p38? MAP-kinaasin, lisääntyminen sepelvaltimoissa ateroskleroottisten plakkien 
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kehittymisen myötä. Kyseistä molekyyliä tutkittiin tarkemmin viljellyissä ihmisen 
makrofageissa, mikä johti uuden tulehdusta säätelevän reitin löytymiseen. Tulokset 
osoittivat, että p38? MAP-kinaasin aktivoituminen on keskeinen säätelijä 
kolesterolikiteiden laukaisemassa inflammasomi-aktivaatiossa. 
Ateroskleroottisten sairauksien hoito perustuu tällä hetkellä pääsääntöisesti 
veren kolesterolipitoisuutta alentavaan lääkitykseen. Valtimon seinämän 
tulehdusmekanismien tarkka selvittäminen luo perustan uudentyyppisen, kroonista 
tulehdustilaa hillitsevän lääkityksen kehittämiseen tämän kansanterveydellisesti 
merkittävän taudin hoitoon.
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1 INTRODUCTION
‘As expected, it ended in a coronary thrombosis. Obviously, when the fats build up, 
the passage ways became completely blocked, we couldn’t get through anymore.’
- A red blood cell in Once upon a time…life, episode 7, The heart –
This simple view on development of atherosclerosis was presented to me early in 
childhood by the educational cartoon “Once upon a time…life” (original title: ”Il était 
une fois...la Vie”; in Finnish “Olipa kerran elämä”) created in 1986 by the French 
screenwriter and cartoonist Albert Barillé (1920-2009). The level of accuracy and 
detail presented in the 26 episodes of the series is astonishing. The very same series 
also introduced me with the immune system and white blood cells, presented as 
the patrolling policemen of the circulation (innate immune cells) and the army 
special task forces releasing swarms of insect-like antibodies to fight the invading 
microbes (adaptive immune cells). Since then, I have learnt a great deal more about 
cardiovascular disease and the underlying process of atherosclerosis, involving not 
only build-up of fats but also chronic inflammation and profound changes in the 
vessel wall architecture.
Atherosclerosis is a slowly progressing degenerative disease of the large arteries 
that may ultimately trigger myocardial infarction or stroke, the leading causes of 
death worldwide. The word ‘atherosclerosis’ refers to the hardening (from Greek 
skleros, meaning hard) of the arterial walls and deposition of fatty substances, fibrous 
material, and immune cells to form a plaques with porridge-like consistency (from 
Greek athere, meaning porridge). The disease may develop without symptoms for 
decades, but sudden complications arise upon plaque rupture and thrombosis that 
obstructs the blood flow through the artery. The most abundant immune cells in 
atherosclerotic plaques are the macrophages, innate immune cells that attempt to 
restore homeostasis by phagocytic clearance of the accumulating lipids. These lipids 
are derived from plasma lipoproteins, the major carriers of cholesterol and other lipids 
in circulation. Low density lipoprotein (LDL), or ‘bad cholesterol’ in layman’s terms, 
has a pivotal role in plaque development. However, researchers in the 21st century 
have increasingly acknowledged the key role of inflammatory reactions in disease 
development (Hansson 2011, Libby 2015). 
The hypothesis on defective lipid metabolism as the driver of atherosclerosis 
began to formulate in the early 20th century. Landmark studies by Ignatowski and 
Anitschkow showed that feeding of rabbits with a diet rich in animal protein or in 
pure cholesterol triggered atherosclerosis (Buja 2014). The theory was later fuelled 
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by epidemiological studies in the 1950’s showing a correlation between plasma 
cholesterol levels and cardiovascular complications in large population studies, 
including the Framingham study (Dawber 1957). Discovery of the LDL receptor 
and advances in understanding the regulation of cholesterol metabolism made by 
Brown and Goldstein in the 1970’s and 80’s further fortified the lipid hypothesis 
of atherosclerosis and earned them a Nobel Prize in 1985 (Brown 1974, Anderson 
1977, Brown 1980, Brown 1986).
The inflammatory nature of atherosclerotic plaques was acknowledged by several 
pathologists and physicians already in the 19th century, but these observations were 
largely neglected amidst the cholesterol frenzy of the 20th century. Most notably, 
the German pathologist Rudolph Virchow proposed a role for inflammation in the 
atheromatous process in his highly influential work Cellular Pathology (Virchow 1863). 
Virchow described two distinct early pathological processes in the vessel walls: “the 
simple fatty metamorphosis” and “a stage of irritation preceding the fatty metamorphosis, 
comparable to the stage of swelling, cloudiness, and enlargement which we see in other 
inflamed parts”. He concludes “in admitting an inflammation of the inner arterial coat to 
be the starting point of the so-called atheromatous degeneration“. In his discussion on more 
advanced stages of the disease, Virchow describes “the chronic inflammatory processes 
going on in the deeper parts [of aorta]” and the rupture of atheromatous depots, causing 
“just as destructive results, as we see in the course of other violent inflammatory processes”. 
Thus, Virchow postulated the involvement of inflammatory processes throughout 
all stages of atherosclerosis, based on purely observational studies of human vessels. 
It took some 140 years, however, before a major paradigm shift began, marked 
by a review article titled Atherosclerosis – an inflammatory disease by the renowned 
pathologist Russell Ross published in 1999 (Ross 1999). According to the modern 
view, atherosclerosis involves a complex interplay between lipid accumulation and 
the inflammatory responses of arterial wall cells and recruited immune cells to these 
lipids (Hansson 2011, Libby 2015).
The purpose of this study was to elucidate the role of a pro-inflammatory signaling 
pathway called the inflammasome in atherosclerosis. The inflammasome pathway was 
discovered in 2002 in macrophages, the key immune cells involved in all stages of 
atherosclerotic plaque development (Martinon 2002). The inflammasome pathway 
controls the maturation and secretion of two potent proinflammatory cytokines, 
interleukin(IL)-1? and -18, that accelerate atherosclerosis in mouse models (Kirii 
2003, Elhage 1998, Mallat 2001b, Elhage 2003). The triggers of inflammasome 
activation and secretion of IL-1? and -18 in atherosclerotic plaques were, however, 
unknown. We thus set out to identify such triggers in cultured macrophages and 
to analyse the expression of the inflammasome pathway in human atherosclerotic 
lesions.
18   
2 REVIEW OF THE LITERATURE
2.1 MACROPHAGES
Macrophages are integral cells of the innate immune system that perform both 
immune surveillance and homeostatic functions. Resident macrophages are found in 
almost all healthy human tissues. This is not a scattered population of few patrolling 
cells here and there. Instead, resident tissue macrophages form a relatively ordered 
network comprising ~10 % of cells in many tissues (Sasmono 2003). Macrophages 
are stellate cells typically occupying a niche in close contact with endothelial or 
epithelial cells. Tissue macrophages, dendritic cells, and blood monocytes, together 
with their bone marrow precursors, form the mononuclear phagocyte system 
( Jenkins 2014). As described by Elie Metchnikoff in the 19th century (Metchnikoff 
1892), the key function of macrophages is continuous phagocytosis of material, 
both host-derived and microbial, from their surroundings (from Greek: makros, 
“large”, and phagein, “eat”). However, resident tissue macrophages develop highly 
specialized functions related to their niche. Heterogeneity and plasticity are, indeed, 
the defining features of macrophages. An excellent summary of the importance of 
macrophages in host defence was recently presented by Prof. David Hume (Hume 
2008): “A reasonable definition of a pathogen is a microorganism that evades constitutive 
killing by macrophages.” 
In the following sections, some of the key aspects of macrophage biology will 
be briefly discussed, pertaining to characteristics common to most macrophage 
populations.
2.1.1 Origin and populations of tissue macrophages
According to the traditional view, resident tissue macrophages differentiate from 
circulating bone marrow –derived monocytes that extravasate into tissues (Hume 
2008, van Furth 1968). However, it is now known that this model is much too 
simplified (Davies 2013). Thus, some tissue macrophage populations, such as the 
microglia in the brain, are established already during the prenatal period from the 
yolk sac (Ginhoux 2010), whereas others, including the Langerhans cells in the skin, 
are derived from the foetal liver (Hoeffel 2012). 
This heterogeneity extends to the maintenance of the various tissue macrophage 
populations. For example, tissue macrophages in the gut are short-lived and 
replenished almost exclusively by blood monocytes infiltrating the tissue ( Jenkins 
2014). Conversely, alveolar macrophages are long-lived and self-renewal occurs via 
local proliferation. Most often, both self-renewing and monocyte-derived macrophage 
populations co-exist in the same tissue, as exemplified by macrophages residing in 
19
the peritoneum and in the liver ( Jenkins 2014). Furthermore, the tissue macrophage 
population can be rapidly expanded during infection or injury via enhanced 
recruitment of blood monocytes, guided by locally produced chemoattractants and 
adhesion molecules. Current knowledge suggests that the same monocyte subset – 
CD16-negative in humans corresponding to Ly6C-high in mice (Ingersoll 2010) – is 
recruited from blood both during steady-state and during inflammation ( Jakubzick 
2013, Epelman 2014). However, during inflammation, the recruited monocytes 
more readily differentiate into tissue macrophages, rather than continue migration 
as monocytes to the draining lymph nodes.
Regardless of their origin, the differentiation, survival, and proliferation of all 
tissue macrophages is maintained by constant secretion of macrophage colony-
stimulating factor (M-CSF) by stromal cells and signaling via its receptor, CSF1R 
( Jenkins 2014). The balance between M-CSF secretion and consumption defines 
the size of a tissue macrophage population at any given time. M-CSF-null mice 
show markedly diminished populations of blood monocytes and tissue macrophages 
and exhibit marked developmental defects in bones, the pancreas, and the nervous 
system, as well as infertility (Hume 2008, Wiktor-Jedrzejczak 1982). Intriguingly, 
comparison of these mice to CSF1R-deficient mice revealed an alternative CSF1R 
ligand, interleukin-34, that supports macrophage survival in the brain and in the 
skin (Davies 2013, Dai 2002, Lin 2008). Furthermore, additional cues specific for 
each niche further define the phenotypes of tissue macrophages, resulting in vast 
heterogeneity as shown by transcriptomic analysis performed in the Immunological 
Genome Project (Gautier 2012).
2.1.2 Clearance of apoptotic cells – a common homeostatic function
While immune surveillance is a common task for all macrophages, the range of tissue-
specific homeostatic functions of macrophages is vast. Bone marrow macrophages 
support erythropoiesis, whereas splenic macrophages phagocytose senescent red blood 
cells and regulate iron metabolism and storage; the microglia in the brain remove 
dead neurons and participate in synaptic remodelling; the lung macrophages regulate 
the amount of pulmonary surfactant in the alveoli; finally, macrophages in white 
and brown adipose tissue regulate insulin sensitivity and adaptive thermogenesis, 
respectively (Davies 2013). Nevertheless, phagocytic removal of senescent, apoptotic, 
or otherwise dysfunctional or damaged cells and debris is a recurrent theme. This 
is no small enterprise; for instance, some 1010 red blood cells are produced every 
hour in the bone marrow balanced by similar clearance rates (de Back 2014). The 
clearance of apoptotic cells by professional phagocytes proceeds via a coordinated 
series of events involving migration, recognition, engulfment, and degradation of 
the target cell (Poon 2014). Importantly, the process is immunologically silent, a 
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defining feature differentiating it from the phagocytic clearance of microbes or 
membrane-permeabilized necrotic cells. 
Chemotactic signals produced by apoptotic cells, the so-called ‘find-me signals’, 
guide phagocytes to the dying target cell. These include the nucleotides ATP and 
UTP that are released via the pannexin-1 channel during early apoptosis (Chekeni 
2010) and recruit phagocytes by signaling via the P2Y2 receptor (Elliott 2009). 
Furthermore, apoptotic cells release chemokine-carrying microparticles, as well as 
lysophosphatidyl choline via caspase-3-mediated activation of calcium-independent 
phospholipase A2 (Truman 2008, Lauber 2003). Both act as chemoattractants 
for monocytes and macrophages. Subsequently, ‘eat-me signals’ on the surface of 
apoptotic cells are required to direct the physical interaction with phagocytes (Poon 
2014). Increased exposure of the inner plasma membrane leaflet lipid phosphatidyl 
serine (PS) provides the most crucial eat-me signal (Fadok 1992). The phagocytic 
cells recognize exposed PS moieties both via direct interaction of PS with several 
receptors - including BAI1, Tim4, and stabilin-2 (Park 2007a, Miyanishi 2007, 
Park 2008) - and via PS-binding bridging molecules (Poon 2014). In addition to 
PS receptors, several other receptor classes expressed on macrophages and other 
innate immune cells contribute to the recognition and engulfment of apoptotic cells, 
including scavenger receptors, complement receptors, and certain pattern recognition 
receptors, most notably CD14 (Devitt 2011). Finally, the concurrent loss of ‘do-not-
eat-me’ signals from the target cell is required to trigger engulfment (Poon 2014). 
Taken together, these redundant mechanisms reflect the essential role of apoptotic 
cell clearance both in homeostatic functions and in host defence, and highlight the 
key role of surface-exposed PS in this process. 
2.1.3 Immune surveillance by macrophages
The macrophages are cells of the innate immunity and, as such, belong to the first 
line of defence against pathogens. The innate immune cells have evolved several 
mechanisms to discriminate between self and non-self, between infectious pathogens 
and harmless commensals, as well as mechanisms to detect ‘missing self ’ and ‘modified 
self ’ (Medzhitov 2009). These mechanisms rely on germline-encoded receptors, 
secreted recognition molecules, signaling components, and effector molecules 
designed to recognize and eliminate a broad spectrum of pathogens. 
Many of the key concepts in innate immune recognition evolved through 
experimentation utilizing insects as a model system. Pioneering work by Hans Boman 
and co-workers first demonstrated the humoral, non-specific, and inducible nature 
of the immune response in the fruit fly Drosophila melanogaster (Boman 1972), 
and identified the first secreted antimicrobial peptides using the giant silk moth 
Hyalophora cecropia (Steiner 1981). Based on the rapid bacterial killing mediated by 
the antimicrobial peptides found accross the animal kingdom, Boman also noted 
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that the term ‘instant immunity’ could have been more suited to describe our innate 
immune system (Boman 2003). Others showed that the induction of antimicrobial 
peptides in Drosophila was controlled by promoter sites resembling the binding sites of 
an inducible mammalian transcription factor, nuclear factor ?B (NF-?B) (Engström 
1993, Kappler 1993). NF-?B had been implicated as a transcriptional regulator of 
immediate early immune response to pathogens (Baeuerle 1994), thus suggesting the 
existence of a conserved control mechanism between insect immunity and the innate 
immune response in mammals. Marco Rosetto et al. showed in a Drosophila blood 
cell line that the induction of antimicrobial peptide production was controlled by a 
receptor named Toll (Rosetto 1995). Extending these observations, Bruno Lemaitre 
et al. showed that ‘dorsal’, the counterpart of NF-?B in Drosophila, was activated by 
binding of ‘spätzle’, an endogenous ligand induced during fungal infection, to the 
Toll receptor (Lemaitre 1996). Moreover, this Toll-induced signaling pathway was 
essential for antifungal immune responses of the fruit fly, as demonstrated by Toll-
mutant flies (Lemaitre 1996). 
Meanwhile, Charles Janeway had presented in 1989 a very influencial theory on 
innate immune recognition, yet his theory was not yet backed up by experimental 
evidence (Medzhitov 2009, Janeway 1989). Janeway proposed that the initial 
detection of invading micro-organisms in the body is achieved by recognition 
molecules on innate, rather than adaptive immune cells. These hypothetical germline-
encoded receptors would recognize general structural motifs conserved among many 
pathogens, termed ‘pathogen-associated molecular patterns’. An alternative theory 
by Polly Matzinger proposed that rather than recognizing the pathogen, innate 
immune system is alerted by ‘danger signals’ released from host cells upon tissue 
injury (Matzinger 1994). Experimental evidence for Janeway’s pattern recognition 
theory was provided by the discovery of mammalian Toll homologues, named Toll-
like receptors (TLR), that mediated NF-?B activation and antimicrobial responses 
via direct binding of microbial ligands (Medzhitov 1997, Poltorak 1998, Yang 1998). 
Similarly, Matzinger’s danger theory has received experimental support from several 
studies identifying modified or ‘out-of-place’ endogenous molecules that trigger 
immune responses, many of them even acting upon the same receptors as microbial 
stimuli (Bryant 2015). Thus, though the original theories by Janeway and Matzinger 
were to some extent opposing, today both aspects of innate immune recognition are 
well-appreciated. 
2.1.3.1 Pattern recognition receptors 
Innate immune cells have developed a wide selection of germline-encoded pathogen 
sensor molecules expressed at the cell surface, the cytoplasm, as well as in the 
intracellular vesicle compartments (Medzhitov 2009). These molecules are called 
pattern recognition receptors (PRRs) according to their ability to recognize conserved 
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microbial structures. Ligand binding to PRRs triggers various intracellular signaling 
cascades that culminate in the activation of key transcription factors controlling the 
mRNA expression of pro-inflammatory cytokines and chemokines, costimulatory 
molecules, and antiviral interferons (Takeuchi 2010). Some cytoplasmic PRRs 
assemble into a caspase-1-activating signaling platform called the inflammasome, 
which mediates the proteolytic maturation and unconventional secretion of the 
pro-inflammatory cytokines interleukin-1??and -18 (Latz 2013).
PRRs expressed in macrophages include TLRs, C-type lectin receptors (CLRs), 
RIG-I-like receptors (RLRs), pyrin and HIN domain containing proteins (PYHINs), 
and nucleotide-binding domain and leucine-rich repeat containing proteins (NLRs) 
(Takeuchi 2010, Schattgen 2011) (Fig.1). The TLRs are transmembrane proteins in 
charge of immune surveillance at the cell surface and endolysosomal compartments. 
The TLRs recognize a wide range of microbial structures and endogenous danger 
signals, as discussed in the following section. The CLRs are expressed at the cell 
surface and mediate proinflammatory cytokine expression in response to fungal 
cell wall carbohydrates (Kingeter 2012). The RLRs are cytoplasmic RNA helicases 
that recognize viral double-stranded RNA, triggering primarily antiviral responses 
(Yoneyama 2004). Similarly, cytoplasmic/nuclear PYHINs recognize bacterial and 
viral double-stranded DNA and trigger antiviral interferon responses (Unterholzner 
2010) or inflammasome assembly (Hornung 2009, Fernandes-Alnemri 2009). 
Finally, the cytoplasmic NLRs respond to diverse microbial components, toxins, 
and endogenous danger signals. Some NLRs trigger pro-inflammatory cytokine 
expression (Inohara 1999, Ogura 2001), while others mediate inflammasome 
assembly (Latz 2013). 
The activation of macrophages solely via direct PRR-mediated recognition of 
pathogens, sometimes referred to as “innate activation” (Gordon 2003), occurs in 
the absence of any contribution by adaptive immune cells. The ensuing release of 
inflammatory mediators by resident tissue macrophages alerts the local tissue cells 
and initiates the rapid recruitment of further innate immune cells from circulation 
into the site of infection or injury. The adaptive immune responses mounted by T and 
B lymphocytes arriving later at the inflamed site are shaped by the ongoing innate 
response. Conversely, macrophages are profoundly affected by the mediators released 
by T lymphocytes, as discussed in section 2.1.6.
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Figure 1. Macrophage pattern recognition receptors involved in immune surveillance. 
The PRRs at the cell surface detect mainly carbohydrates, lipoproteins, and lipids present 
in bacterial and fungal cell walls, as well as certain endogenous ligands acting as danger 
signals. The cytoplasmic and endosomal PRRs include a large variety of receptors recognizing 
microbial nucleic acids, as well as the NLR family recognizing diverse microbial and endogenous 
molecules. Two PRRs have been identiﬁed from the human PYHIN family, the DNA sensors 
AIM2 (depicted) and IFI16 (not depicted, mainly nuclear). The PRRs from different families 
share some of the functional domains involved in ligand recognition (LRR) and homotypic 
domain-domain interactions (CARD, PYD). CRD, carbohydrate recognition domain; ITAM, 
immunoreceptor tyrosine-based activation motif; LRR, leucine-rich repeat domain; TIR, Toll/
IL-1 receptor domain; CARD, caspase activation and recruitment domain; PYD, pyrin domain; 
NOD, nucleotide-binding and oligomerization domain; HIN, hematopoietic interferon-inducible 
nuclear protein domain.
2.1.3.2 Immune recognition via opsonisation 
Various soluble molecules can mark pathogens for indirect recognition by 
macrophages. These molecules are collectively referred to as ‘opsonins’, a name 
derived from Greek and translating roughly to ‘supplying or preparing food’. In 
the context of host defence, the interaction of opsonins with macrophage receptors 
triggers efficient phagocytosis and microbial killing by oxidative burst or cytolytic 
activity towards a damaged or infected host cell, accompanied by the release of 
inflammatory mediators. Notably, the recognition of opsonins may also result in 
immunologically silent uptake, as exemplified by clearance of apoptotic cells via 
bridging molecules that, in fact, function as opsonins in the process (Poon 2014). 
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Antibodies produced by B lymphocytes are the prototypical opsonins that enhance 
the uptake of microbes by phagocytic cells. The constant Fc regions of different 
immunoglobulin classes are recognized by the Fc receptors widely expressed in 
hematopoietic cells, including the macrophages. Fc? receptors recognize the most 
abundant immunoglobulin class, IgG, and trigger phagocytosis via inducing receptor 
clustering and signal transduction that drives the reorganization of actin cytoskeleton 
for target engulfment (Goodridge 2012, Nimmerjahn 2008). The Fc? receptors 
generally bind IgG with low affinity. Therefore, coordinated receptor interaction 
with multivalent ligands, such as IgG-opsonized particles or immune complexes, is 
required to overcome the low affinity barrier (Goodridge 2012, Nimmerjahn 2008). 
The humoral arm of the innate immunity also includes many opsonins, such 
as soluble pattern recognition molecules and components of the complement 
system. These molecules are synthesized mainly in the liver, but also innate immune 
cells and endothelial cells can produce a subset of them (Bottazzi 2010). Soluble 
pattern recognition molecules include pentraxins, collectins, and ficolins that can 
be considered functional ancestors of antibodies (Bottazzi 2010). Notably, the 
pentraxins, such as C-reactive protein, bind various microbial structures and act 
as Fc? receptor ligands or trigger further opsonisation by complement (Bharadwaj 
1999, Lu 2008, Roumenina 2006). The complement system comprises a large group 
of plasma proteins that trigger a complex hierarchical protease cascade leading to 
opsonisation of microbes and damaged or infected host cells. Complement activation 
can also directly trigger membrane permeabilization and lysis of the target microbe 
or host cell. The classical route and the lectin route of complement activation are 
both initiated by soluble pattern recognition molecules, the C1q and the collectins 
or ficolins, respectively (Bottazzi 2010). C1q binds to microbes and dying cells and 
mainly regulates homeostatic processes, whereas collectins and ficolins promote 
enhanced phagocytosis of pathogens via their various receptors on immune cells 
(Bottazzi 2010). Complement activation not only boosts the phagocytotic clearance 
of microbes and damaged or infected host cells by macrophages, but triggers also 
macrophage activation and the release of proinflammatory mediators (Hänsch 1984).
2.1.4 Toll-like receptors: The prototypes of pattern recognition
Discovery of the mammalian TLR family was based on homology with the 
Drosophila Toll receptor involved in antifungal immune responses (Rosetto 1995, 
Lemaitre 1996, Medzhitov 1997, Poltorak 1998). Unlike the Drosophila Toll, the 
vertebrate TLRs directly recognize and bind microbial components and thus act 
as true PRRs. Ten functional TLRs (TLR 1-10) have been identified in humans, 
and the TLRs 1-9 conserved between humans and mice have been extensively 
characterized (Bryant 2015, Kawai 2010). The TLRs are transmembrane proteins 
characterized by 1) leucine-rich repeat (LRR) domain facing the extracellular space 
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or lumen of the endolysosomal vesicles and 2) Toll-interleukin-1 receptor (TIR) 
domain facing the cytoplasm. The LRR domain mediates ligand binding, whereas 
the TIR domain initiates downstream signaling by the activated receptor. 
2.1.4.1 TLR ligands
The TLRs recognize and bind to a wide array of bacterial, viral, protozoan, and fungal 
ligands that include proteins, lipids, sugar moieties, and nucleic acids. Traditionally, 
the TLRs are grouped into two groups according to their subcellular localization 
(Fig. 2). TLRs 1, 2, 4, 5, and 6 are expressed on the cell surface, where they co-
operate to detect lipids or proteins found in the surface structures of microbes, 
including the cell wall and the flagellae involved in bacterial locomotion (Bryant 
2015, Kawai 2010). The other group comprises TLRs 3, 7, 8, and 9 trafficking 
between the endoplasmic reticulum, endosomes, and lysosomes, where they detect 
microbial nucleic acids (Bryant 2015, Kawai 2010). Notably, TLRs 2 and 4 at the 
cell surface are activated also by several endogenous ligands, sometimes referred to 
as danger or damage-associated molecular patterns. For example, the nuclear protein 
high mobility group box 1 released upon tissue injury activates both TLR2 and 
TLR4 (Tsung 2005, Park 2006) and the chaperone heat shock protein 60 activates 
TLR4 (Ohashi 2000). Furthermore, TLRs 2 and 4 recognize extracellular matrix 
components released or modified during inflammation and tissue injury, such as 
hyaluronan, heparan sulfate, biglycan, and fibronectin extra domain A (Termeer 
2002, Johnson 2002, Schaefer 2005, Okamura 2001).  
2.1.4.2 TLR activation and downstream signaling
Upon ligand binding, most TLRs homodimerize or, in the case of some cell surface 
TLRs, heterodimerize (Fig. 2). Thus, TLR2:TLR1 heterodimer binds triacylated 
bacterial lipopeptides ( Jin 2007), whereas TLR2:TLR6 heterodimer recognizes 
diacylated lipopeptides (Kang 2009). In addition to the presence of an appropriate 
ligand, activation of certain TLRs requires additional accessory molecules (Lee 2012). 
TLR4, the sensor of lipopolysaccharide (LPS) derived from cell walls of Gram-
negative bacteria, offers a good example. LPS binds TLR4 only when complexed 
with the LPS-binding protein, and the co-receptor cluster of differentiation 14 
(CD14) facilitates the transfer of this complex to TLR4 (Lee 2012). Finally, myeloid 
differentiation 2 (MD-2), a soluble protein that associates with TLR4, is essential for 
TLR4 activation by LPS and both MD-2 and TLR4 participate in LPS recognition 
(Lee 2012). Notably, CD14 binds also many other TLR ligands and facilitates their 
delivery to the TLRs (Lee 2012). Similarly, the scavenger receptor CD36 is required 
for binding of certain ligands to the TLR2:6 dimer (Lee 2012).
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Figure 2. TLR signaling. Both the MyD88 and TRIF adapters initiate a TAK1-mediated cascade 
that results in activation of IKK, phosphorylation of I?B, and the nuclear translocation of NF-
?B. In parallel, TAK1 activates the p38 and JNK MAPK cascades leading to AP-1 activation. The 
TRIF-mediated TAK1 signaling is omitted for clarity. In addition, TRIF triggers the activation of 
noncanonical IKKs, the TBK1 and IKK?, that mediate the phosphorylation and activation of IRF3 
and IRF7. The TLR4 is unique among TLRs in that it triggers both an early MyD88-dependent 
response and a late TRIF-dependent response after receptor endocytosis. See the text for 
further details. AL, acylated lipopeptide; AP-1, activator protein 1; CD, cluster of differentiation; 
I?B, Inhibitor of ?B; IKK, Inhibitor of ?B kinase; IRF, interferon regulatory factor; JNK, c-Jun 
N-terminal kinases; LPS, lipopolysaccharide; LRR, leucine-rich repeat domain; MD-2, myeloid 
differentiation 2; MyD88, myeloid differentiation primary response 88; NF-?B, nuclear factor 
kappa-light-chain-enhancer of activated B cells; p38, p38 mitogen-activated protein kinases; 
TAK1, transforming growth factor ? -activated kinase; TBK1, TRAF family member -associated 
NF-?B activator -binding kinase 1; TIR, Toll/IL-1 receptor domain; TRIF, TIR domain-containing 
adapter inducing interferon-?. 
After TLR activation, the cytoplasmic TIR domains of TLRs recruit various TIR-
containing adapter molecules that determine the activated downstream signaling 
cascades (Kawai 2010). The signaling adapter myeloid differentiation primary 
response 88 (MyD88) induces proinflammatory cytokine expression by activating 
the transcription factors NF-?B and activator protein 1 (AP-1). Transforming 
growth factor ? -activated kinase (TAK1) is the central hub in MyD88-mediated 
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signaling. TAK1 triggers deactivation of the Inhibitor of ?B (I?B) via activating the 
Inhibitor of ?B kinase (IKK) complex, as well as activation of mitogen-activated protein 
kinase (MAPK) cascades resulting in AP-1 activation (Kawai 2010, Perkins 2007). 
Alternatively, some TLRs recruit the signaling adapter TIR domain-containing 
adapter inducing interferon-? (TRIF). TRIF triggers activation of the TAK1/NF-
?B/AP-1 axis, as well as activation of interferon regulatory factor (IRF) 3 or 7 via 
the non-typical IKK complexes IKK? and TRAF family member -associated NF-
?B activator -binding kinase 1 (TBK1) (Kawai 2010). NF-?B and AP-1 trigger 
the production of proinflammatory cytokines (e.g. IL-1, TNF-?, IL-6), whereas 
IRF3/7 mediates the production of type I interferons involved in antiviral responses. 
2.1.5 Inﬂammatory mediators produced by macrophages
Macrophages produce a myriad of pro- and anti-inflammatory mediators. These 
include a large number of secreted protein mediators, the cytokines, as well as 
various lipid mediators. The key molecules and their functions during inflammatory 
responses are briefly introduced below. 
The cytokines are further divided into several subgroups, including interleukins 
(IL), interferons (IFN), tumor necrosis factor (TNF) family, transforming growth 
factors (TGF), colony-stimulating factors, and chemokines. In response to an 
appropriate stimulus, macrophages are capable of releasing mediators from all these 
subgroups. Stimulation of macrophages with TLR ligands induces the synthesis 
of a key triad of pro-inflammatory cytokines: TNF-?, IL-1?, and IL-6. All three 
cytokines contribute systemically to the induction of acute-phase protein secretion 
by the liver, and, notably, IL-1? also induces fever (Cray 2009, Dinarello 2009). 
TNF? and IL-1?, in particular, are ‘at the top of the food chain’ in cytokine signaling 
networks. They amplify NF-?B activation and trigger the synthesis of countless 
other inflammatory mediators, including chemokines, adhesion molecules, lipid 
mediators, and other pro-inflammatory cytokines (Dinarello 2009, Turner 2014). 
Moreover, IL-1? promotes the activity of T helper (Th) cells, particularly the Th17 
subset (Santarlasci 2013). A major function of IL-6 during inflammation is its 
crucial contribution to maturation of B cells into antigen-producing plasma cells 
(Hirano 1986). Furthermore, IL-12 and IL-18 released by macrophages promote the 
differentiation and IFN-? production of Th1 cells, respectively (Hsieh 1993, Okamura 
1995). Macrophages are also a major source of the widely studied chemokine IL-8, 
a strong chemoattractant for neutrophils (Turner 2014, Hammond 1995). Finally, 
the secretion of type I interferons by macrophages, triggered for example via various 
endosomal and cytoplasmic nucleic acid sensors, orchestrates antiviral processes in 
surrounding cells (Liu 2011). Thus, the interferon-inducible genes encode proteins 
that hinder viral entry to host cells, target viral components for degradation, and 
block budding of virions from the cell membrane.  
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On the other hand, macrophages produce potent anti-inflammatory cytokines, 
including IL-10 and TGF-? that function in resolution of inflammation, tissue repair, 
and maintenance of tolerance (Assoian 1987, Fiorentino 1991). IL-10 promotes 
differentiation of regulatory T cells (Groux 1997) and TGF-? has a wider role in 
regulation of the T cell functions (Li 2006). Both cytokines also act on macrophages 
themselves by dampening the synthesis of pro-inflammatory cytokines (IL-1?/?? 
TNF-?, IL-6) (Fiorentino 1991, Bogdan 1992). Moreover, macrophages also produce 
molecules specifically counteracting the effects of certain pro-inflammatory cytokines, 
such as IL-1 receptor antagonist (Matsushime 1991) and IL-18 binding protein 
(Corbaz 2002). 
Lipid mediators of inflammation have been studied much less compared to 
cytokines, yet recently, some novel roles for lipid mediators have been discovered. 
Macrophages can produce a number of lipid mediators accross all the main subgroups 
(Yang 2011). Arachidonic acid is a polyunsaturated omega-6 fatty acid released 
from membrane phospholipids by phospholipase A2 during inflammation. Further 
enzymatic reactions produce oxidized derivatives called eicosanoids, including 
prostaglandins and leukotrienes that promote vascular permeability, leukocyte 
chemotaxis, pain, and swelling locally at the inflamed site (Serhan 2007). Lipoxins, 
another class of arachidonic acid derivatives, and the newly discovered resolvins, 
protectins, and maresins, are critical for active resolution of inflammation (Serhan 
2007, Buckley 2014). The latter are produced from omega-3 fatty acids. 
Taken together, macrophages are equipped with an impressive arsenal of effector 
molecules that regulate all phases of the inflammatory response. These inflammatory 
mediators form a complex network or synergistic and opposing effects, as well as 
induction and counter-regulation among them. Depending on the mediator, the effects 
may spread systemically or be highly local, acting in an autocrine or paracrine manner.
2.1.6 Macrophage polarization during inﬂammation
Macrophage activation is defined as a transient induction or enhancement of a 
particular effector function in response to a stimulus (Adams 1984). The classical 
microbicidal and tumoricidal effector functions of macrophages are inducible by 
the Th1 cytokine interferon-?, together with a microbial trigger (LPS) (Gordon 
2003, Nathan 1983, Celada 1984, Dalton 1993). The discovery of an alternative 
mode of macrophage activation, inducible by the Th2 cytokines IL-4 or IL-13 (te 
Velde 1988, Stein 1992, McKenzie 1993, Doherty 1993, Doyle 1994), lead to the 
development of a highly influential concept of ‘polarized’ macrophage activation 
(Gordon 2003, Locati 2013). Mills and colleagues proposed the names ‘M1’ and ‘M2’ 
for the classically and alternatively activated macrophages, respectively, reflecting 
the associated Th1 and Th2 type immune responses (Mills 2000). 
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2.1.6.1 Characteristics of M1- and M2-polarized macrophages
The M1-polarized macrophages are characterized by production of high levels of 
pro-inflammatory cytokines (e.g. TNF-?, IL-1?, IL-6), nitric oxide, and reactive 
oxygen species, efficient phagocytosis and bacterial killing by respiratory burst, 
tumoricidal activity, as well as by the ability to promote Th1 and Th17 immune 
responses via production of IL-12 and IL-23 (Gordon 2003, Locati 2013). 
Conversely, the hallmarks of IL-4 or IL-13-elicited M2 macrophages are increased 
mannose receptor activity, enhanced expression of major histocompatibility complex 
II molecules, and attenuation of pro-inflammatory cytokine production (Gordon 
2003, te Velde 1988, Stein 1992, McKenzie 1993, Doherty 1993, Doyle 1994). The 
mannose receptor, suppressed in M1 macrophages, is an endocytic receptor that 
recognizes both endogenous and microbial mannose-containing sugar moieties 
and is involved in the delivery of antigens into professional antigen-presenting cells 
(Gordon 2003, Martinez-Pomares 2012). Furthermore, M2-polarized macrophages 
are characterized by increased activity of arginase 1, an enzyme that converts arginine 
to ornithine that serves as a precursor for polyamines and collagen involved in cell 
growth and matrix production (Modolell 1995, Munder 1998). In contrast, M1 
macrophages suppress the arginase 1 pathway and direct arginine to the synthesis 
of nitric oxide by the inducible nitric oxide synthase, thus promoting the cytotoxic 
and microbicidal effector functions (Modolell 1995, Munder 1998). Notably, also 
other cytokines, including IL-10, IL-21, and IL-33, have been described to induce 
M2-like homeostatic or anti-inflammatory macrophage polarization (Locati 2013).
The M1 polarization represents a stereotype of pro-inflammatory and microbicidal 
macrophage phenotype, whereas the M2 polarization is mainly associated with 
resolution of inflammation. M1-like macrophages are involved in resistance 
against intracellular pathogens, but mediate detrimental effects in autoimmune and 
inflammatory conditions, such as systemic lupus and rheumatoid arthritis (Sica 
2012). Conversely, M2-like macrophages play important roles in host defence 
against parasite infections and contribute to allergies and asthma. However, it is 
important to note that the M1 and M2 phenotypes do not represent static subsets of 
macrophages, but rather, a reversible adaptation of the macrophages to their specific 
microenvironment. For example, a switch from M1-like to M2-like macrophage 
polarization is observed during transition from acute to chronic infection, which likely 
protects against excessive pro-inflammatory cytokine production (Sica 2012). In the 
setting of carcinogenesis, a similar M1-M2 switch and the associated suppression of 
M1-associated antitumor activity may contribute to tumor progression (Sica 2012).
2.1.6.2 Beyond M1/M2: The dynamic continuum of macrophage polarization
The M1/M2 paradigm has served as an invaluable roadmap in guiding the research 
and shaping our conceptions of innate immune function. However, as originally stated 
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by Mills and colleagues (Mills 2000) proposing the M1/M2 classification: “--while 
useful for conceptualizing immune responses, [the classification] certainly could be an 
oversimplification. Instead, there may be a continuum of phenotypes between M-1 and 
M-2 macrophages.” Indeed, this firmly anchored dichotomous view of macrophage 
activation has often been interpreted without acknowledging its inherent restrictions 
(Martinez 2014). Analyses of tissue macrophages in disease have revealed mixtures 
of complex phenotypes poorly predictable from the in vitro models (Martinez 
2014). To this end, the various ‘omics’ approaches offer tools to comprehensively 
characterize macrophage phenotypes and the underlying regulatory networks in 
an unbiased manner. For example, a large-scale transcriptomic analysis of primary 
human macrophages stimulated with 28 different stimuli identified a dynamic 
spectrum of expression signatures, comprising core signatures common to several 
activation states complemented by stimulus-specific additional modules (Xue 2014).
Other approaches include studying the effects of epigenetic modulation and 
noncoding microRNAs on macrophage polarization and plasticity. The histone 
demethylase Jumonji domain containing 3 is crucial in the epigenetic regulation of 
M2 polarization both in vitro and in vivo, and required for M2 macrophage -mediated 
host defence against helminth infection (Ishii 2009, Satoh 2010). Moreover, a histone 
methyltransferase, SET and MYND domain-containing 2,  negatively regulates 
M1 polarization of macrophages by suppressing the expression of proinflammatory 
cytokines, major histocompatibility complex II molecules, and costimulatory molecules 
(Xu 2015). The microRNA miR-155 downregulates the expression of interleukin 13 
receptor ?1 and represses IL-13-induced gene expression in human macrophages, 
thus attenuating M2 polarization (Martinez-Nunez 2011). Conversely, miR-223 
suppresses M1 polarization and drives M2 polarization of macrophages, which was 
protective against obesity-induced adipose tissue inflammation (Zhuang 2012).
Another emerging research field is the effect of macrophage energy metabolism 
on their inflammatory functions. A metabolic switch to aerobic glycolysis occurs 
during M1, but not during M2 activation of macrophages, resembling the well-
established Warburg effect in cancer cells (Rodriguez-Prados 2010, Tannahill 2013, 
Warburg 1956). Moreover, the glycolytic switch was required for the synthesis of 
IL-1?, a key M1 cytokine (Tannahill 2013). Remarkably, this concept extends also 
to other innate and adaptive immune cells; the energy metabolism of pro- and anti-
inflammatory subtypes are dominated by glycolysis and oxidative phosphorylation, 
respectively (O’Neill 2013). 
These new approaches are rapidly reshaping the paradigm of macrophage activation 
and polarization, yet many study setups are still fundamentally based on the old M1/
M2 paradigm. A comprehensive understanding of macrophage activation is emerging 
that highlights the dynamic and multidimensional nature of macrophage activation, 
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extending far beyond the M1/M2 dichotomy (Schultze 2015). The ultimate goal is 
to integrate the various aspects of regulation – transcriptional, post-transcriptional, 
epigenetic, and metabolic – into an overall model that will greatly deepen our 
understanding of macrophage biology and enable specific modulation of macrophage 
activation to combat inflammatory diseases.
2.2 THE INFLAMMASOME PATHWAY
The inflammasome is a key pro-inflammatory signaling pathway active in cells 
of the innate immunity. The term was coined by late Prof. Jürg Tschopp and his 
research group at the University of Lausanne, who discovered the pathway from 
monocyte-macrophages (Martinon 2002). The name refers to the structural and 
functional similarities of the inflammasome with an apoptotic signaling pathway, 
the apoptosome (Martinon 2009, Chai 2014). Both pathways involve cytoplasmic 
sensor molecules that upon activation assemble a large intracellular protein complex 
that functions as a caspase activation platform. Members of the NLR and PYHIN 
families serve as the sensor molecules initiating inflammasome complex assembly, 
which results in activation of an inflammatory caspase, the caspase-1 (Strowig 2012). 
Caspase-1 mediates the proteolytic maturation and secretion of the proinflammatory 
cytokines IL-1? and IL-18, as well as a highly proinflammatory form of cell death 
called pyroptosis (Strowig 2012).
Triggers of the inflammasome pathway include both microbial components and 
sterile endogenous danger signals. Accordingly, the inflammasome pathway is involved 
both in host defence and in chronic inflammatory diseases. Macrophages are the 
prototypical inflammasome pathway-expressing cells with high levels of inflammasome 
activity. Varying levels of inflammasome activity have been demonstrated also in 
other innate immune cells, including dendritic cells and neutrophils (Sharp 2009, 
Bakele 2014), and in certain non-immune cells, such as keratinocytes (Feldmeyer 
2007). The first human diseases associated with impaired inflammasome pathway 
function were a group of rare autoinflammatory diseases called cryopyrin-associated 
periodic syndromes that are caused by mutations in one of the inflammasome sensor 
molecules, the NLRP3 (also known as CIAS1, cryopyrin, and NALP3) (Hoffman 
2001, Aksentijevich 2002, Feldmann 2002). Today, the inflammasome pathway 
has been linked also to a growing number of common metabolic diseases involving 
chronic inflammation (Robbins 2014). Moreover, the inflammasome pathway has 
important roles in host defence against intracellular bacteria and viruses (Vanaja 
2015), as well as in regulation of intestinal homeostasis (Chen 2014). The focus of 
this chapter will lie in the activation mechanisms of the inflammasome. Moreover, 
the NLRP3 inflammasome and its role as a mediator of sterile inflammation will be 
given a special emphasis.
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2.2.1 The NLR and PYHIN family proteins: Initiators of 
inﬂammasome assembly 
The human NLR and PYHIN families comprise 22 and 4 members, respectively 
(Ting 2008, Cridland 2012). Of these, three NLR proteins – NLRP1, NLRP3, and 
NLRC4 – and the PYHIN protein absent in melanoma 2 (AIM2) have been firmly 
established as cytoplasmic sensor/receptor molecules that initiate inflammasome 
complex assembly (Vanaja 2015). In addition, few other members of the NLR and 
PYHIN families, and even one protein outside these families (pyrin) have putative 
functions as initiators of inflammasome complex assembly (Vanaja 2015). Of note, 
the inflammasome complexes are named after the sensor/receptor molecule initiating 
their assembly, e.g. the NLRP1 inflammasome. The fourth letter after NLR in the 
nomenclature of NLR proteins signifies the N-terminal effector domain (e.g. NLRC 
for NLR family CARD domain containing and NLRP for NLR family pyrin 
domain containing) (Ting 2008).
Many NLR family proteins have also well-characterized functions independent of 
the inflammasome pathway. NLRC5 and NLRA/CIITA are nuclear transactivator/
enhancer proteins essential for transcription of the antigen-presenting class I and class 
II human leukocyte antigen (HLA) molecules, respectively (Meissner 2010, Robbins 
2012, Steimle 1993, Steimle 1994). Moreover, NLRC1/NOD1 and NLRC2/NOD2 
act as cytoplasmic PRRs that mediate NF-?B activation (Inohara 1999, Ogura 2001). 
Conversely, NLRP6 and NLRP12 may suppress TLR-mediated NF-?B activation 
to regulate gut microbiota and homeostasis (Chen 2014). The PYHIN family was 
discovered as a cluster of interferon-inducible genes on mouse chromosome 1 
(Ludlow 2005). Whereas the NLR family functions are focused on inflammation, 
the PYHINs serve mixed functions related also to DNA damage response, cell cycle 
regulation, and tumor suppression (Ludlow 2005). 
The sensor molecules triggering inflammasome complex assembly show distinct, yet 
partially overlapping expression patterns. NLRP1 and NLRP3 proteins are expressed 
in various cultured immune cells, including monocytes, macrophages, neutrophils, and 
lymphocytes (Kummer 2007). Notably, NLRP3 protein is expressed at a low level 
in resting primary immune cells, but the expression is inducible by stimulation with 
TLR ligands (Kummer 2007, Bauernfeind 2009). In normal human tissues, NLRP1 
staining was found in leukocytes of lymphoid organs and in alveolar macrophages 
(Kummer 2007). In contrast, NLRP3 stained negative in lymphoid tissues, implying 
inducible expression in immune cells also in vivo. Moreover, NLRP1 and NLRP3 
proteins are differentially expressed in epithelial cells along the gastrointestinal and 
respiratory tracts, cervix, and bladder (Kummer 2007). NLRC4 mRNA was detected 
in human bone marrow, lymphoid organs, placenta, and brain (Poyet 2001), whereas 
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AIM2 mRNA was found in spleen, small intestine, testis, and peripheral blood 
leukocytes (DeYoung 1997). 
Other crucial inflammasome pathway components include the adapter protein 
ASC (apoptosis-associated speck-like protein containing a caspase activation and 
recruitment domain) and the caspase-1 protease. ASC protein is widely expressed in 
human tissues, e.g. in epithelial cells of colon, tonsil, and skin, as well as in monocytes 
and alveolar macrophages (Masumoto 2001). Finally, caspase-1 mRNA is expressed 
in human bone marrow, lymph nodes, spleen, and placenta (Druilhe 2001). Taken 
together, the inflammasome pathway components are strongly expressed in immune 
cells and epithelial cells at barrier sites, in good agreement with the function of these 
receptors in immune surveillance. 
2.2.2 Mechanisms of inﬂammasome assembly
The core components of inflammasome complexes variably express two functional 
domains from the death domain superfamily: the pyrin domain (PYD) and the 
caspase activation and recruitment domain (CARD) (Ting 2008, Cridland 2012, 
Park 2007b). Before the discovery of the inflammasome pathway, other death domain 
-containing proteins were known to assemble into diverse signaling complexes via 
homotypic domain interactions, resulting in the activation of NF-?B and apoptotic 
caspases (Park 2007b). Furthermore, the death domain superfamily family member 
Apaf-1 that assembles the apoptosome complex was found to bear an overall 
domain structure similar to NLRs, which provided a working model for studying 
NLR function (Martinon 2002, Poyet 2001). Apaf-1 binds cytochrome c via its 
WD40 repeat domain, which relieves an autoinhibitory conformation (Chai 2014). 
This enables the self-oligomerization of Apaf-1 via its nucleotide-binding and 
oligomerization domain into a ring-shaped septamer, which allows the recruitment 
of caspase-9 to Apaf-1 via CARD-CARD interaction. Indeed, similar mechanisms 
were later found to govern inflammasome assembly. 
2.2.2.1 Domain structures of inﬂammasome complex components
The inflammasome-forming NLRs, as well as AIM2, are cytoplasmic proteins 
maintained as inactive monomers in the absence of activating stimuli. Interaction 
with the chaperone heat-shock protein 90 and the ubiquitin ligase SGT1 is required 
for stabilization of the NLR monomers into an inactive but signaling-competent 
state (Mayor 2007). Moreover, the C-terminal leucine-rich repeat (LRR) domain 
of NLRs is required for maintenance of the protein in an autoinhibitory state (Ting 
2008, Poyet 2001, Agostini 2004, Faustin 2007, Kofoed 2011) (Fig. 3). In addition 
to the LRR, the NLRs harbour a central nucleotide-binding and oligomerization 
domain (NOD) and an N-terminal death domain, either a PYD or a CARD, that 
mediates the recruitment of binding partners downstream NLR activation (Ting 
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2008). NLRP1 is unique among the NLR family in that it harbours two additional 
domains, a filamin interactin domain and a CARD, at the C-terminus distal to 
the LRR region. As discussed in detail in sections 2.2.4 and 2.2.5, the activation 
mechanisms of inflammasome-forming NLRs are rather complex and involve 
accessory NLR proteins that aid in ligand sensing. Similar to NLRP1/3, AIM2 
harbours an N-terminal PYD that is followed by a C-terminal PYHIN family 
signature domain, the ‘hematopoietic interferon-inducible nuclear protein domain’ 
(HIN) (Cridland 2012). AIM2 directly binds to its activating ligand, cytoplasmic 
double-stranded DNA (Hornung 2009, Fernandes-Alnemri 2009, Bürckstümmer 
2009, Roberts 2009). The HIN domain maintains AIM2 in an autoinhibitory state, 
which is relieved by the binding of DNA to HIN ( Jin 2012). The ASC adapter 
comprises a PYD and a CARD domain, connected by a short flexible linker region 
of 23 amino acids (de Alba 2009). Finally, the caspase-1 protease is expressed as 
an inactive zymogen, pro-caspase-1, that comprises an N-terminal CARD and the 
p10/p20 catalytic subunits (Thornberry 1992).
2.2.2.2 Inﬂammasome complex assembly 
Upon detection of an appropriate activator in the cytoplasm, the autoinhibitory state 
of the NLR or PYHIN receptor is relieved and a conformational change enables self-
Figure 3. Domain structures of the inﬂammasome complex components. Domains are 
listed from N- to C-terminus. PYD, pyrin domain; CARD, caspase activation and recruitment 
domain; NOD, nucleotide-binding and oligomerization domain; LRR, leucine-rich repeat 
domain; FIIND, ﬁlamin interactin domain; HIN, hematopoietic interferon-inducible nuclear 
protein domain; WD, WD40 repeat domain. The p10 and p20 represent the catalytic subunits 
of caspase-1, connected by a short linker region that is cleaved during caspase-1 activation. 
The Apaf-1 scaffold protein mediating apoptosome assembly is shown for comparison. See the 
details in text.
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oligomerization of the receptor and recruitment of downstream binding partners (Fig. 
4). NLR oligomerization is mediated via the NOD domain and requires nucleotide 
binding (Faustin 2007, Duncan 2007, Lu 2005). The lack of oligomerization domain 
in AIM2 seems to be bypassed by the simultaneous binding of several AIM2 
molecules on a multivalent DNA ligand to achieve oligomerization ( Jin 2012). 
Activated NLR or PYHIN receptor then recruits caspase-1 either via direct CARD-
CARD interaction, as in the case of NLRC4, or via recruitment of the ASC adapter 
to their PYD domains (Fig. 4A) (Martinon 2002, Hornung 2009, Fernandes-
Alnemri 2009, Poyet 2001, Agostini 2004). After recruitment to the NLR or AIM2 
oligomer, ASC forms complex multimeric structures via self-association and greatly 
amplifies the amount of available CARD domain interaction sites (de Alba 2009, Lu 
2014). ASC seems to enhance even the function of the CARD-containing NLRC4 
(Mariathasan 2004, Miao 2006, Zhao 2011). Recruitment of pro-caspase-1 to the 
nascent inflammasome complex then occurs via interaction of ASC CARD domains 
with caspase-1 CARD domains. Finally, proximity-induced autocleavage of the 45 
kDa pro-caspase-1 into the 10 kDa and 20 kDa subunits forming the catalytically 
active enzyme takes place in the inflammasome complex (Poyet 2001, Wilson 1994).
Figure 4. Inﬂammasome complex assembly and structure. (A) Schematic model of 
domain-domain interactions during inﬂammasome assembly. (B) A structural model of the 
NLRP3 inﬂammasome complex based on studies of puriﬁed inﬂammasome components. The 
AIM2 inﬂammasome complex is highly similar, except that rather than as a ring structure, the 
AIM2 oligomerization proceeds linearly along the DNA ligand. See the details in text. 
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2.2.2.3 Structure of the inﬂammasome complexes
The exact stoichiometries and structures of the various inflammasome complexes 
still remain a mystery. In agreement with the earliest studies (Masumoto 2001), the 
formation of a single perinuclear ~1 ?m aggregate of ASC was later demonstrated 
upon activation of both NLR and AIM2 inflammasomes in countless reports. This 
“ASC speck” forms rapidly after inflammasome activation and colocalizes with other 
inflammasome components, suggesting that these structures represent the cytokine-
processing unit (Fernandes-Alnemri 2009, Fink 2008, Baroja-Mazo 2014, Man 
2014). The purified NLR receptors form ring-shaped oligomers reminiscent of the 
apoptosome (Faustin 2007, Halff 2012) (Fig. 4B). Moreover, structural analysis of 
purified inflammasome components suggested that a single, ordered stalk-like ASC 
polymer extends from the NLRP3 or AIM2 receptor oligomer, offering a nucleation 
point for multiple caspase-1 filament structures (Lu 2014) (Fig. 4B). In agreement, 
the NLRP3/ASC inflammasome complex formed in macrophage cytoplasm 
comprised a ~1-2 ?m aggregate of fibrillar structures emanating from a single core 
(Baroja-Mazo 2014, Franklin 2014). However, it was recently proposed that smaller, 
oligomeric NLRP3/ASC assemblies spreading throughout the cytoplasm,  rather 
than the large speck structure, would be the major sites of cytokine processing 
(Compan 2015). A further level of complexity is introduced by the simultaneous 
activation of several inflammasome-forming receptors during bacterial infection 
of macrophages, resulting in the colocalization of the receptors in a single speck 
structure (Man 2014).
2.2.3 Downstream effects of inﬂammasome activation
Caspase-1 triggers both major downstream effects of inflammasome activation: 
1) the proteolytic maturation of the proforms of IL-1? and IL-18 into their 
biologically active, secreted form and 2) pyroptotic cell death associated with further 
pronflammatory effects. 
2.2.3.1 Proinﬂammatory cytokine secretion
Caspase-1 cleaves pro-IL-1? and pro-IL-18 after an aspartic acid residue (Asp116 
in IL-1?, Asp37 in IL-18) in a conserved recognition sequence, which removes 
an N-terminal propiece and yields the biologically active cytokine (Dinarello 
2009, Thornberry 1992, Ghayur 1997). These cytokines lack the signal sequence 
that normally directs secreted proteins into the classical endoplasmic reticulum/
Golgi-mediated secretory pathway. Thus, IL-1? and IL-18 are secreted via an 
unconventional mechanism that remains poorly defined, yet it is closely coupled to 
caspase-1 activity (Dubyak 2012). Notably, not only the mature cytokines, but also 
the procytokines and all inflammasome components are secreted from the cell in 
the process (Martinon 2002, Baroja-Mazo 2014, Franklin 2014). Over the years, 
37
many mechanisms have been proposed, including specialized secretory lysosomes, 
exosomes, or autophagosomes, microvesicle shedding, or plasma membrane pore 
formation (Andrei 2004, Qu 2007, Dupont 2011, MacKenzie 2001, Pizzirani 
2007, Fink 2006). Importantly, caspase-1 seems to be a more general mediator 
of unconventional protein secretion. A proteomic approach revealed 77 candidate 
molecules secreted via a caspase-1-dependent mechanism (Keller 2008). Among 
these, IL-1? and fibroblast growth factor 2 were verified as molecules secreted by 
a caspase-1-dependent mechanism, yet these targets were not cleaved by caspase-1.
The secretion of IL-1? and IL-18 is central for the role of the inflammasome 
pathway in various inflammatory diseases, whereas pyroptotic cell death is important 
for inflammasome-mediated host defence, as discussed below. Mature IL-1? binds 
to a heterodimer of IL-1 receptor I and IL-1 receptor accessory protein that is also 
activated by the close homolog IL-1? (Dinarello 2009). The signaling events triggered 
by this IL-1 receptor dimer closely resemble TLR signaling due to the shared TIR 
domain (see section 2.1.4). Thus, MyD88 recruitment to the receptor results in 
proinflammatory cytokine expression via NF-?B and p38/JNK MAPK cascades 
that activate AP-1. IL-1? triggers a broad range of inflammatory effects, such as 
nitric oxide-mediated vasodilatation and prostaglandin E2 production resulting in 
fever (Dinarello 2009). Moreover, IL-1? induces the expression of various adhesion 
molecules and chemokines, promoting extravasation of immune cells to the inflamed 
tissue site. IL-1? is also essential in differentiation of Th17 cells (Santarlasci 2013). 
Mature IL-18 signals by binding to a dimer formed by IL-18 receptor ? and ? 
chains, and, similar to IL-1 receptor 1, the receptor utilizes TIR domains to recruit 
MyD88 for downstream signaling via NF-?B and AP-1 (Dinarello 2009). IL-18 is 
best known as an inducer of interferon-? production by T cells, thus contributing to 
Th1 type immune responses (Okamura 1995). However, IL-18 induces interferon-??
only in the presence of IL-12; when IL-12 is absent, IL-18 contributes to the 
development of Th2 type immune responses e.g. via induction of IL-4 (Dinarello 
2009). The marked roles of IL-1??and IL-18 in inflammation are further underscored 
by the expression of specific negative regulators of IL-1 and IL-18 signaling: the 
IL-1 receptor antagonist (Matsushime 1991), the soluble IL-1 receptor II acting as 
a decoy (Colotta 1993), and IL-18 binding protein (Novick 1999). 
2.2.3.2 Pyroptotic cell death
Pyroptotic cell death is an essential effector mechanism for inflammasome-mediated 
host defence, typically occurring after robust caspase-1 activation by microbial 
stimuli (Bergsbaken 2009). IL-1? and IL-18 are secreted also during inflammasome 
activation that involves pyroptosis, yet pyroptosis is the major effector mechanism 
of inflammasome-mediated clearance of intracellularly replicating bacteria in vivo 
(Miao 2010a). Nevertheless, also inflammasome-mediated cytokine secretion 
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contributes host defence, for example by controlling early virus replication in vivo 
(Rathinam 2010).
Pyroptosis is a form of programmed cell death that is distinguished from other 
forms of cell death primarily by caspase-1-dependence. Caspase-1-dependent plasma 
membrane pore formation during pyroptosis results in rapid cell swelling, osmotic 
lysis, and spillage of proinflammatory cytoplasmic contents (Fink 2006). Pyroptosis 
is independent of apoptotic caspases and both mitochondrial and nuclear integrity 
are preserved during pyroptotic cell death, further distinguishing it from apoptosis 
(Bergsbaken 2009). Furthermore, the caspase-1-mediated maturation and secretion 
of IL-1? and IL-18 is not required for execution of pyroptosis (Monack 2001, Le 
Feuvre 2002), and thus other caspase-1 targets initiate the pyroptotic cell death 
program. Caspase-1 digestome of THP-1 macrophage lysates identified 41 caspase-1 
cleavage targets, of which only 30 % were shared with the crucial apoptotic effector 
caspase-3 (Shao 2007). Among these, major target groups were glycolytic enzymes, 
cytoskeletal components, RNA and protein synthesis machinery, chaperone proteins, 
as well as proteins involved in cellular trafficking. However, the crucial caspase-1 
targets and mechanisms mediating pyroptosis remain to be elucidated.
2.2.4 The host defence inﬂammasomes: NLRP1, NLRC4, and AIM2
The NLRP1, NLRC4, and AIM2 inflammasomes are cytoplasmic pathogen sensors 
activated by conserved microbial structures, toxins, and bacterial/viral nucleic acids. 
Accordingly, these inflammasomes have important roles in host defence against 
bacteria, viruses, and parasites. The activators and activation mechanisms of the 
NLRP1, NLRC4, and AIM2 inflammasomes are introduced in this section and 
summarized in Table 1.
2.2.4.1 NLRP1
The NLRP1 inflammasome complex was first discovered from heat-activated 
cellular extracts of monocyte-macrophages (Martinon 2002). Muramyl dipeptide, 
a component of bacterial cell wall peptidoglycan, was subsequently shown to activate 
the NLRP1 receptor in human macrophages (Faustin 2007, Bruey 2007). However, 
direct binding of this ligand to NLRP1 could not be demonstrated (Reubold 2014). 
Instead, muramyl dipeptide may be bound by another cytoplasmic NLR, NOD2, 
that subsequently co-oligomerizes with NLRP1 to form an active inflammasome 
complex (Hsu 2008). The NLRP1 receptor is also required for IL-1? secretion 
in response to the intracellular parasite Toxoplasma gondii in a human monocyte 
cell line (Witola 2011). Similarly, T. gondii infection elicits a caspase-1 and ASC-
dependent IL-1? response in mouse macrophages (Ewald 2014). The magnitude 
of IL-1? response to T. gondii was correlated with different NLRP1b alleles in 
different mouse strains, and caspase-1 was crucial for controlling the parasite burden 
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in infected mice (Ewald 2014). Finally, the mouse ortholog NLRP1b, but not human 
NLRP1, is activated in macrophages upon direct cleavage by the anthrax lethal 
toxin metalloprotease (Boyden 2006, Chavarria-Smith 2013). The access of this 
key virulence factor of Bacillus anthracis to macrophage cytoplasm was required for 
subsequent caspase-1 activation, target cytokine cleavage, and pyroptosis (Fink 2008). 
Interestingly, the IL-1? response of mouse macrophages to B. anthracis and anthrax 
lethal toxin is also dependent on NOD2 (Hsu 2008), implying a conserved NOD2-
dependent activation mechanism of NLRP1 in mice and men. Beyond host defence, 
Table 1. Summary of the activators of the NLRP1, NLRC4, and AIM2 inﬂammasomes.
Activators Physiological 
relevance 
References
NLRP1 inﬂammasome
Muramyl dipeptide of bacterial cell 
wall (human NLRP1)
Bacillus anthracis and anthrax lethal 
toxin (mouse NLRP1b)
Toxoplasma gondii                              
(human NLRP1 and mouse NLRP1b)
Host defence, bacteria
Host defence, bacteria
Host defence, parasites
(Faustin 2007, Bruey 2007, 
Hsu 2008)
(Fink 2008, Hsu 2008, 
Boyden 2006)
(Witola 2011, Ewald 2014)
NLRC4 inﬂammasome
Flagellin proteins of ﬂagellae                  
(via mouse NAIP5 and NAIP6)
Rod proteins of type III secretion 
systems (via mouse NAIP2)
Needle proteins of  type III secretion 
systems (via mouse NAIP1 and 
human NAIP)
Intracellularly replicating bacteria
Host defence, bacteria
Host defence, bacteria
Host defence, bacteria
Host defence, bacteria
(Kofoed 2011, Miao 2006, 
Zhao 2011, Franchi 2006)
(Kofoed 2011, Zhao 2011, 
Miao 2010b)
(Zhao 2011, Yang 2013)
(Mariathasan 2004, Miao 
2010a)
AIM2 inﬂammasome
Synthetic dsDNA (poly-(dA:dT)
Genomic DNA
Bacterial DNA
DNA viruses
Intracellularly replicating bacteria
None
Autoimmune/ 
autoinﬂammatory 
diseases?
Host defence, bacteria
Host defence, viruses
Host defence, bacteria
(Hornung 2009, Fernandes-
Alnemri 2009, Bürckstümmer 
2009, Roberts 2009)
(Fernandes-Alnemri 2009, 
Roberts 2009)
(Fernandes-Alnemri 2009) 
(Hornung 2009, Rathinam 
2010)
(Rathinam 2010, Fernandes-
Alnemri 2010, Saiga 2012)
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NLRP1 polymorphisms have been associated with various autoimmune disorders, 
e.g. celiac disease and vitiligo, and identification of the underlying mechanisms will 
help to further elucidate NLRP1 function (Zhong 2013). 
Recent studies have revealed a peculiar feature regarding NLRP1b-mediated 
activation of caspase-1 in mouse macrophages. NLRP1b harbours a CARD domain 
and can thus recruit caspase-1 directly for activation of caspase-1, bypassing the 
requirement for ASC adapter. In accord, activation of NLRP1b with anthrax lethal 
toxin in ASC-deficient macrophages elicits considerable amounts of pyroptosis and 
IL-1? release, showing only a mild dependence on ASC (Van Opdenbosch 2014, 
Guey 2014). However, the autoproteolytic cleavage of caspase-1 into the active 
p10/p20 subunits is abolished in lethal toxin-treated ASC-deficient macrophages. 
Remarkably, it was demonstrated that NLRP1b, but not NLRP3, NLRC4, or AIM2, 
was able to activate caspase-1 in its full-length form, without inducing caspase-1 
autoproteolysis (Van Opdenbosch 2014, Guey 2014). This fundamentally new aspect 
in regulation of caspase-1 activity calls for further studies to deepen our understanding 
of  caspase-1 activation mechanisms. 
2.2.4.2 NLRC4
The interaction of NLRC4 with caspase-1 and the resulting caspase-1 activation 
was first discovered in overexpression studies of this Apaf1-related protein (Poyet 
2001). The bacterial motor protein flagellin from Salmonella typhimurium was later 
identified as an activator of the NLRC4 receptor in cultured mouse macrophages 
(Mariathasan 2004, Miao 2006, Franchi 2006). Flagellin triggered IL-1??secretion 
by macrophages, as well as pyroptotic death of the cells. Later on, conserved rod 
and needle proteins of various bacterial type III secretion systems (Zhao 2011, 
Miao 2010b, Yang 2013), as well as flagellins from various pathogenic bacteria 
(Zhao 2011) were shown to trigger NLRC4 activation. Intriguingly, NLRC4 seems 
to function as an adapter molecule analogous to ASC function. The NLR family 
apoptosis inhibitory proteins (NAIPs) were identified as the sensor molecules 
that directly bind NLRC4 activators providing ligand specificity, and subsequently 
co-oligomerize with NLRC4 to activate caspase-1 (see details on NAIP ligand 
specificity in Table 1) (Kofoed 2011, Zhao 2011, Yang 2013). The NAIP/NLRC4 
inflammasomes have a crucial role in limiting the replication of intracellular bacteria 
in macrophages in vitro and in vivo, which is dependent on inflammasome-mediated 
pyroptotic cell death, rather than on IL-1??and IL-18 secretion (Miao 2010a). 
Moreover, the NAIP/NLRC4 inflammasome contributes to discrimination between 
pathogenic and commensal bacteria by the intestinal phagocytes (Franchi 2012). 
In 2014, the first reports mechanistically linking genetic variants of NLRC4 to 
human disease were recently published (Canna 2014, Romberg 2014). Two de novo 
mutations causing spontaneous hyperactivation of NLRC4 were discovered from 
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patients suffering distinct yet overlapping autoinflammatory diseases. The shared 
symptoms included periodic fever, high plasma levels of IL-1 family cytokines, and 
gastrointestinal pathologies (Canna 2014, Romberg 2014). The latter is in good 
agreement with the role of NLRC4 in regulation of intestinal homeostasis and 
recognition of bacteria that cause enteric inflammation (Mariathasan 2004, Franchi 
2012).
2.2.4.3 AIM2
Four independent reports originally identified AIM2 as a cytoplasmic sensor of 
double-stranded DNA (dsDNA) that triggers inflammasome complex assembly 
(Hornung 2009, Fernandes-Alnemri 2009, Bürckstümmer 2009, Roberts 2009). The 
HIN domain of AIM2 directly binds the sugar-phosphate backbone of DNA in a 
sequence-independent, but length-dependent manner and the PYD domain recruits 
ASC and caspase-1 to form a functional inflammasome complex (Hornung 2009, 
Fernandes-Alnemri 2009, Bürckstümmer 2009, Jin 2012). The minimum length of 
DNA able to trigger AIM2-dependent IL-1? response is roughly 80 bp, implying 
that AIM2 utilizes the target DNA as an oligomerization platform ( Jin 2012). 
Activation of the AIM2 inflammasome has been demonstrated during infection with 
various intracellularly replicating bacteria and DNA viruses. Thus, early control of 
mouse cytomegalovirus replication in vivo is dependent on AIM2-mediated IL-18 
secretion (Rathinam 2010). Furthermore, AIM2-KO mice are highly susceptible to 
M. tuberculosis infection with greatly increased bacterial loads in the liver and the 
lungs, and markedly reduced IL-1? and IL-18 levels in bronchoalveolar lavage and 
serum (Saiga 2012). Finally, AIM2 had a major role in controlling bacterial loads 
during F. tularensis infection in mice (Fernandes-Alnemri 2010).
The AIM2 inflammasome can be activated by both genomic and pathogen-
derived DNA (Fernandes-Alnemri 2009), which may imply a role in autoimmune or 
autoinflammatory diseases. Systemic lupus erythematosus (SLE) is an autoimmune 
disease characterized by the presence of autoantibodies against self dsDNA, 
likely arising due to immune activation via defective clearance of apoptotic cells. 
Accumulating evidence suggests a role for AIM2 inflammasome activation in 
SLE. The mouse PYHIN protein p202 is a candidate SLE susceptibility factor 
and a negative regulator of AIM2-dependent caspase-1 activation (Roberts 2009). 
Moreover, AIM2 is activated by DNA derived from apoptotic cells and AIM2 
deficiency dampens inflammation in a mouse model of SLE (Zhang 2013).
2.2.5 The NLRP3 inﬂammasome: Mediator of sterile inﬂammation 
The inflammasome complexes described above serve a primary function in host 
defence against bacterial and viral pathogens. They respond to microbial components 
that enter the cytoplasm during infections via a direct interaction with the 
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inflammasome-activating stimulus, be it a simple receptor-ligand interaction or 
receptor modification by an active virulence mechanism. Microbial components and 
products, such as bacterial and viral RNA and the bacterial ionophore nigericin, 
featured also among the first activators identified for the NLRP3 inflammasome 
(Mariathasan 2006, Kanneganti 2006b, Kanneganti 2006a). Yet, increasingly, the 
NLRP3 inflammasome is studied in the context of sterile inflammation, which will 
also be the focus of this chapter. 
2.2.5.1 The concept of priming
The caspase-1 target pro-IL-18 is expressed constitutively, but pro-IL-1? is absent 
in resting monocytes and macrophages (Puren 1999). Typically, the activators 
of the NLRP3 receptor are not capable of inducing the synthesis of pro-IL-1?? 
Importantly, also the NLRP3 receptor itself is expressed at a limiting level in resting 
macrophages, and induction of NLRP3 synthesis is an important checkpoint for 
NLRP3 inflammasome assembly (Bauernfeind 2009). Transcription of both NLRP3 
receptor and pro-IL-1? can be induced by NF-?B activation, either via TLRs (TLRs 
2, 3, 4, 7, 9) or by certain cytokines (TNF-?) (Bauernfeind 2009, O’Connor 2003, 
Franchi 2009). Yet, these stimuli are ineffective in triggering NLRP3 inflammasome 
assembly and the ensuing proteolytic maturation of the target cytokines. Thus, 
two separate signals are required for the NLRP3 inflammasome assembly and the 
release of biologically active cytokines: 1) a signal that induces the NF-?B-mediated 
transcription of NLRP3 receptor and pro-IL-1?, followed by 2) a signal that triggers 
NLRP3 receptor activation and inflammasome complex assembly, resulting in 
cytokine processing and secretion. The first, transcriptional signal is referred to 
as “priming”, and the stimulation of TLR4 receptors with LPS is considered the 
canonical pathway for priming.
Recent studies have begun to uncover a role also for a post-translational 
modifications in the priming step of NLRP3 inflammasome activation (Elliott 
2015). Thus, deubiquitination of the NLRP3 receptor ( Juliana 2012), as well as 
ubiquitination and phosphorylation of the ASC adapter (Rodgers 2014, Hara 2013) 
were all necessary but not sufficient for activation of the NLRP3 inflammasome. 
However, both the priming signal and the inflammasome activation signal seemed 
to contribute to these post-translational modifications, and the exact pathways 
triggering them remain to be elucidated.
2.2.5.2 Activators of the NLRP3 receptor
Long before the discovery of the inflammasome pathway, high extracellular 
ATP concentration was known to trigger the release of IL-1? from LPS-primed 
macrophages via a mechanism that involved potassium efflux from the cells (Perregaux 
1994). The ATP receptor P2X7 was subsequently identified as the mediator of the 
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ATP-induced potassium efflux and IL-1? release (Ferrari 1997, Solle 2001). The 
P2X7 receptor is an ATP-gated cation channel (K+ out; Ca2+ and Na+ in) that 
also mediates the formation of a larger plasma membrane pore upon prolonged 
stimulation via an unknown mechanism (Dubyak 2012, Sung 1985, Qu 2011). 
Studies in ASC- and NLRP3-deficient mouse macrophages revealed ATP as one 
of the first endogenous triggers of NLRP3 inflammasome activation (Mariathasan 
2006). Notably, in an in vivo model of sterile hepatic injury, ATP release from 
necrotic cells triggers NLRP3-mediated IL-1? secretion that initiates neutrophil 
recruitment to the site of injury (McDonald 2010). 
Also monosodium urate crystals and calcium pyrophosphate dehydrate crystals 
formed in the joints of gout patients were recognized early on as sterile activators 
of the NLRP3 inflammasome (Martinon 2006). This fuelled the search for other 
crystalline and particulate inflammasome activators. Subsequently, the crystalline 
adjuvant alum, and silica crystals and asbestos particles causing fibrotic lung diseases 
were shown to trigger NLRP3 inflammasome in macrophages (Hornung 2008, 
Dostert 2008, Cassel 2008). Similarly, pathological protein aggregates, such as 
amyloid-? peptide deposited in the brain during Alzheimer’s disease and the islet 
amyloid polypeptide forming pancreatic deposits in type II diabetes, were identified 
as NLRP3 inflammasome activators in macrophages and microglia (Halle 2008, 
Masters 2010). NLRP3 inflammasome assembly can be triggered also by extracellular 
matrix components released upon tissue injury. These include the glycosaminoglycan 
hyaluronan and the small leucine-rich repeat proteoglycan biglycan that are associated 
with inflammation in response to sterile renal or skin injury (Babelova 2009, Yamasaki 
2009). Table 2 lists examples of activators of the NLRP3 inflammasome, highlighting 
their heterogeneity in terms of structure and origin. 
2.2.5.3 Intracellular stress signals trigger NLRP3 activation
As the list of the known activators of the NLRP3 receptor keeps on expanding, it 
is clear that the sheer diversity of these activators makes a direct interaction with 
the NLRP3 receptor an unlikely activation mechanism. According to the current 
paradigm, intracellular stress signals triggered by the activators indirectly mediate 
NLRP3 activation (Elliott 2015). Numerous studies have shown that the NLRP3-
mediated IL-1? responses in macrophages variably depend on particle phagocytosis, 
phagosomal acidification, lysosomal destabilization, enhanced production of reactive 
oxygen species (ROS), and potassium efflux from the cells (Perregaux 1994, Hornung 
2008, Dostert 2008, Cassel 2008, Halle 2008, Masters 2010, Cruz 2007, Lopez-
Castejon 2010). Of these, potassium efflux seems to be the only signal universally 
required for NLRP3 inflammasome activation (Petrilli 2007, Munoz-Planillo 2013). 
A drop in the intracellular K+ concentration has been directly demonstrated during 
stimulation with crystalline/particulate NLRP3 activators and with ATP (Perregaux 
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Table 2. Examples of activators of the NLRP3 inﬂammasome.
Activators Physiological relevance References
Endogenous
Extracellular ATP Sterile inﬂammation during tissue 
injury
(Mariathasan 2006, 
McDonald 2010)
Monosodium urate crystals Sterile joint inﬂammation, gout (Martinon 2006)
Calcium pyrophosphate 
dehydrate crystals
Sterile joint inﬂammation, 
pseudogout
(Martinon 2006)
Islet amyloid polypeptide 
oligomers
Sterile pancreatic inﬂammation, type 
II diabetes
(Masters 2010)
Fibrillar amyloid-? peptide Sterile CNS inﬂammation, 
Alzheimer’s disease
(Halle 2008)
Prion protein ﬁbrils/aggregates Sterile CNS inﬂammation, prion 
diseases
(Hafner-Bratkovi??
2012)
Biglycan (proteoglycan) Sterile inﬂammation during tissue 
injury
(Babelova 2009) 
Hyaluronan (glycosaminoglycan) Sterile inﬂammation during tissue 
injury
(Yamasaki 2009)
Endoplasmic reticulum stress Metabolic stress –associated diseases (Menu 2012)
Complement activation Inﬂammatory diseases, host defence (Laudisi 2013)
Cell swelling induced by hypo-
osmolarity 
Clinical use of hypertonic solutions 
to ameliorate inﬂammation
(Perregaux 1996, 
Compan 2012)
Exogenous
Pore-forming toxins (nigericin, 
maitotoxin)
Host defence, bacteria and 
protozoans
(Mariathasan 2006)
Ribotoxic ricin toxin Lethal poison from the plant Ricinus 
communis
(Lindauer 2010)
Bacterial and viral RNA Host defence, bacteria and viruses (Kanneganti 2006b, 
Kanneganti 2006a)
Aluminum salt (alum) crystals Adjuvant function in vaccines (Hornung 2008) 
Poly(lactide-co-glycolide) and 
polystyrene microparticles
Adjuvant function in vaccines (Sharp 2009)
Silica crystals Silicosis, lung inﬂammation and 
ﬁbrosis
(Hornung 2008, 
Dostert 2008, 
Cassel 2008) 
Asbestos ﬁbres/particles Asbestosis, lung inﬂammation and 
ﬁbrosis
(Dostert 2008) 
Hemozoin crystals                  
(derived from heme)
Host defence, blood-feeding 
parasites incl. malaria
(Dostert 2009, Shio 
2009)
Nanoparticles used in cosmetics Skin inﬂammation, lung 
inﬂammation 
(Yazdi 2010)
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1994, Munoz-Planillo 2013). Nevertheless, the K+ efflux is a signal shared with other 
inflammasome complexes and likely plays a permissive, rather than a decisive role in 
NLRP3 inflammasome activation (Fink 2008, Fernandes-Alnemri 2010). Similar to 
K+ efflux, cellular Cl-, Na+, and Ca2+ fluxes, as well as changes in cell volume coupled 
to various regulatory mechanisms triggering fluxes of ions and water, have been 
linked with NLRP3 activation (Perregaux 1996, Compan 2012, Perregaux 1998, 
Schorn 2010, Murakami 2012, Rabolli 2014).
Both crystalline/particulate NLRP3 activators and ATP cause lysosomal 
destabilization and the release of lysosomal contents into the cytoplasm (Hornung 
2008, Halle 2008, Masters 2010, Lopez-Castejon 2010). A single lysosomal protease, 
cathepsin B, markedly contributed to the IL-1? response induced by crystals and 
particles. Furthermore, cathepsin B inhibition blocked K+ efflux during NLRP3 
activation, suggesting that cathepsin B release from lysosomes may act upstream 
K+ efflux (Munoz-Planillo 2013). Notably, the inhibitor CA-074-Me widely used 
to block cellular cathepsin B activity also inhibits the closely related cathepsin L 
(Montaser 2002). Indeed, genetic ablation of either cathepsin B or L attenuated 
NLRP3-mediated IL-1? responses, yet not for all activators (Halle 2008, Munoz-
Planillo 2013, Duewell 2010). These data suggest redundant roles for lysosomal 
cathepsins in NLRP3 inflammasome activation. 
Cellular ROS production is enhanced by crystalline/particulate NLRP3 activators 
and by ATP, and general inhibitors of ROS often block NLRP3-mediated IL-
1? secretion (Dostert 2008, Cassel 2008, Cruz 2007). However, the interpretation 
is complicated by the inhibitory effects of these compounds on the transcription 
of NLRP3 receptor and pro-IL-1? (Bauernfeind 2009, van de Veerdonk 2010, 
Bauernfeind 2011). Intriguingly, thioredoxin-binding protein, released from the 
ROS-detoxifying protein thioredoxin upon ROS production, was suggested to act 
as a direct NLRP3-activating ligand (Zhou 2010). However, the results could not 
be repeated in another study (Masters 2010). The major cellular sources of ROS in 
macrophages are the mitochondrial respiratory chain and the phagosomal NADPH 
oxidase involved in microbial killing (Terada 2006). Knocking out NADPH oxidase 
components has yielded controversial results in mouse macrophages regarding a 
role in NLRP3 inflammasome activation (Hornung 2008, Dostert 2008). However, 
the data from NADPH oxidase -defective patient monocytes confirmed that the 
NADPH oxidase is dispensable for NLRP3 activation (van de Veerdonk 2010). 
Conversely, the role of mitochondrial ROS (mitROS) is now intensively studied.
Most, but not all, NLRP3 activators trigger mitROS production, and scavenging 
of mitROS diminishes NLRP3 activation (Elliott 2015). Induction of mitROS by 
respiratory chain inhibitors or by blocking the autophagic clearance of damaged 
mitochondria induces spontaneous NLRP3 activation in macrophages and further 
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sensitizes them to NLRP3 activation by ATP and crystals (Zhou 2011, Nakahira 
2011). Intriguingly, a partial loss of mitochondrial membrane potential was associated 
with elevated mitROS and NLRP3 activation, whereas a full collapse did not trigger 
mitROS or IL-1? release (Zhou 2011). Thus the level of mitochondrial stress and 
damage may define the decision between inflammasome activation and apoptosis. 
Finally, NLRP3, ASC, mitochondria, and endoplasmic reticulum markers colocalized 
in the perinuclear region during inflammasome activation (Zhou 2011, Misawa 
2013). 
Taken together, potassium efflux, enhanced mitROS formation, and lysosomal 
destabilization may all contribute to activation of the NLRP3 inflammasome (Fig. 
5). The relative importance of these stress signals, as well as the detailed mechanisms 
ultimately triggering NLRP3 receptor activation, remain elusive. The NLRP3-
activating stress signals may act in parallel or in a sequence, and, most likely, two or 
more signals are required for triggering NLRP3 activation. Intriguingly, all three 
stress signals have been implicated also in activation of the apoptosome complex, 
again highlighting the close connection between these pathways (Gross 2011).
2.2.5.4 Role in autoinﬂammatory syndromes and chronic inﬂammatory diseases
Cryopyrin-associated periodic syndromes (CAPS) are a group of three rare, 
inherited, autoinflammatory syndromes caused by mutations in the NLRP3 receptor 
(Hoffman 2001, Aksentijevich 2002, Feldmann 2002). These include familial 
cold autoinflammatory syndrome, Muckle–Wells syndrome, and neonatal onset 
multisystem inflammatory disease (Aksentijevich 2011). The term autoinflammatory 
distinguishes these disorders of the innate immune system from antibody and T 
cell-mediated autoimmune diseases. The shared symptoms of CAPS include recurrent 
episodes of fever, arthritis, and rashes. Mutations underlying CAPS cause NLRP3 
hyperactivation, resulting in uncontrolled, spontaneous secretion of inflammasome 
target cytokines by monocytes (Aksentijevich 2002, Dowds 2004). These findings 
rapidly led to successful treatment of CAPS patients with the recombinant human 
IL-1 receptor antagonist, anakinra, showing dramatic improvement of the symptoms 
(Hawkins 2003, Goldbach-Mansky 2006). 
Today, the NLRP3 inflammasome has been mechanistically linked to a wide range 
of chronic inflammatory diseases, including gout, asbestosis, silicosis, obesity-induced 
inflammation and type II diabetes, as well as Alzheimer’s disease (Robbins 2014, 
Zhong 2013). The NLRP3 inflammasome contributes to joint inflammation in a 
mouse model of gout (Amaral 2012), and the inflammatory and fibrotic responses to 
asbestos or silica in the lungs are dependent on the NLRP3 inflammasome (Dostert 
2008, Cassel 2008). Furthermore, knock-out (KO) mouse models have established a 
role for the NLRP3 inflammasome in the development of obesity-induced adipose 
tissue inflammation and insulin resistance (Vandanmagsar 2011, Stienstra 2011). 
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Strikingly, caspase-1 activation was demonstrated in the brain of Alzheimer’s disease 
patients, and NLRP3- or caspase-1-deficiency in a mouse model of Alzheimer’s 
disease was highly protective against loss of spatial memory (Heneka 2013). Finally, 
polymorphisms in the gene encoding the NLRP3 receptor are associated with several 
autoimmune diseases, including psoriasis, type I diabetes, and celiac disease (Zhong 
2013). Taken together, the NLRP3 inflammasome is emerging as a major regulator 
of sterile inflammation that contributes to a broad range of diseases associated with 
chronic inflammation, metabolic disturbances, and ageing.
2.3 ATHEROSCLEROSIS – A CHRONIC INFLAMMATORY DISEASE
Atherosclerosis is the underlying cause of myocardial infarction and stroke, the 
leading causes of death worldwide. It is a slowly progressing disease of the large 
arteries strongly associated with lifestyle and aging. Focal development of lipid-rich, 
inflamed deposits, called atherosclerotic ‘plaques’ or ‘lesions’, along the arterial tree is 
the hallmark of disease pathogenesis. The prominent risk factors for atherosclerosis 
and cardiovascular disease are age, male sex, hypertension, smoking, obesity associated 
with impaired  glucose tolerance or overt diabetes, high LDL cholesterol, low high 
density lipoprotein (HDL) cholesterol, and high triglycerides (Fruchart 2004). In 
Figure 5. Proposed activation mechanisms of the NLRP3 inﬂammasome.  See the text for 
details. AP-1, activator protein 1; ATP, adenosine triphosphate; mitROS, mitochondria-derived 
reactive oxygen species; NF-?B, nuclear factor kappa-light-chain-enhancer of activated B cells; 
P2X7R, P2X7 receptor; TLR, Toll-like receptor; TNFR, TNF-? receptor.
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addition, high-sensitivity C-reactive protein, a liver-derived general marker of low 
grade inflammation, is used clinically in cardiovascular risk assessment (Koenig 
2013). Thus, atherosclerosis is a highly multifactorial disease affected by a wide 
range of metabolic variables, defined as the total ‘cardiometabolic risk’ of a person 
(Despres 2008).
Atherosclerotic plaque development, or ‘atherogenesis’, in the arterial wall begins 
from tunica intima, a layer comprising the luminal endothelium and the underlying 
connective tissue (Stary 1992). The intima is further divided into a subendothelial 
proteoglycan-rich layer that contains scattered tissue macrophages and smooth muscle 
cells (SMCs) of the synthesizing phenotype, and a deeper musculoelastic layer rich 
in collagen, elastic fibers, and SMCs of the contractile phenotype (Stary 1992). 
An internal elastic lamina separates the intima from tunica media, a highly ordered 
structure of contractile SMCs layered within elastic fibers and collagen. Finally, an 
outer layer of loose connective tissue, called tunica externa or adventitia, surrounds 
the media. The adventitia hosts lymphatics and small blood vessels, vasa vasorum, 
essential for flux of nutrients and metabolic waste to and from the arterial wall 
(Nakano 2005). Notably, the healthy intima is avascular and thus dependent on the 
adventitial lymphatics and blood vessels. 
2.3.1 Lipoproteins and the initiation of atherosclerotic lesion 
development
Lipoproteins are the major carriers of circulating neutral lipids, notably cholesteryl 
esters and triglycerides. The main function of lipoproteins is to provide a convenient 
package for transportation of the hydrophobic lipids to peripheral tissues for use 
as a source of energy or as structural components. A diet rich in cholesterol and 
saturated fats results in elevated levels of circulating lipoprotein-carried cholesterol, 
which in turn has a definitive role in development of atherosclerosis. Lipoproteins 
come in many different shapes, sizes, and lipid/protein compositions, and they can 
be divided into subclasses based on their buoyant densities. Of these, the subclasses 
of LDL and HDL play crucial, yet opposing roles in atherogenesis. 
2.3.1.1 Retention of native LDL in the arterial intima
LDL is a globular 20-25 nm particle packing cholesteryl esters and triglycerides 
in its core, wrapped in a phospholipid/cholesterol monolayer that embeds a large 
multifunctional protein, the apolipoprotein (apo)B-100 (Hevonoja 2000). Liver 
secretes very low density lipoprotein (VLDL), and the removal of triglycerides 
from circulating VLDL into peripheral tissues generates first intermediate density 
lipoprotein (IDL) (Brown 1986). Further removal of triglycerides from IDL 
generates the cholesterol-enriched LDL that is cleared back to the liver via LDL 
receptors (LDLR) (Brown 1986). 
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Elevated plasma levels of LDL promote selective accumulation of LDL particles 
into the arterial walls at branch points and curvatures of the arterial tree. The altered 
hemodynamic forces at these sites induce changes in the phenotype of the vascular 
endothelial cells and loosening of the endothelial tight junctions, as well as adaptive 
thickening of the intima (Stary 1992, Tabas 2015). These changes increase the entry 
of LDL into the subendothelial intima and the transit distance of LDL to adventitial 
lymphatics (or back to the vessel lumen), rendering the sites highly susceptible 
to atherosclerotic lesion development (Kovanen 1990). Once in the intima, LDL 
accumulates in the extracellular matrix via ionic interactions between clusters of 
positively charged residues on apoB-100 and negatively charged matrix proteoglycans 
(Camejo 1990). Abundant accumulation of LDL in the intimal matrix is detectable 
by electron microscopy already 2 hours after bolus injection of human LDL into 
rabbits  (Nievelstein 1991). These observations led to the formulation of the ‘response-
to-retention theory’ of atherosclerotic lesion development (Williams 1995). The 
theory postulates that the earliest event in lesion development is the subendothelial 
retention of native LDL in the extracellular matrix proteoglycans of the intima. 
The positions of the key amino acid residues in apoB-100 mediating the LDL-
proteoglycan interactions were later identified (Boren 1998). Moreover, these residues 
were mutated in a landmark study by Skålén et al., demonstrating their crucial role 
in the LDL-proteoglycan interaction and in the initiation of atherosclerotic lesion 
development in mice (Skålén 2002).
2.3.1.2 Modiﬁcation of LDL triggers massive lipid uptake and inﬂammation
Once trapped within the matrix proteoglycans, the LDL particles become exposed 
to oxidative, lipolytic, and proteolytic modifications, eliciting fusion and aggregation 
of the particles and further hindering their exit from the intima (Hevonoja 2000, 
Öörni 2000). Moreover, LDL modification enables accelerated cellular uptake of 
LDL by creating recognition sites for ‘scavenger receptors’ (SR), such as SR-A1, 
SR-B1, and CD36 (Canton 2013). The SRs form a heterogeneous group of PRRs 
that were originally identified based on their affinity for modified lipoproteins, 
but are now known to mediate the clearance of diverse endogenous and microbial 
ligands (Canton 2013). Native LDL is internalized by cells via the LDLR pathway 
(Brown 1980). The ensuing influx of cholesterol suppresses LDLR expression and 
cholesterol biosynthesis, so preventing accumulation of excess cellular cholesterol. 
In contrast, the uptake of modified LDL by SRs is not downregulated by cellular 
cholesterol content, allowing the massive accumulation of cholesteryl esters stored as 
cytoplasmic droplets within macrophages and other SR-expressing cells (Goldstein 
1979, Brown 1979). This morphological transformation of macrophages into lipid 
droplet-filled ‘foam cells’ is the hallmark of early atherosclerotic lesions (Stary 1994). 
Modified LDL species trigger also proinflammatory activation of resident 
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arterial wall cells. In this context, oxidized LDL (oxLDL), detected in plaques in 
situ (Haberland 1988, Palinski 1989), has been the subject of intensive research. It 
was recently shown that binding of copper-oxidized LDL to the SR CD36 triggers 
the formation of a heterotrimeric CD36:TLR4:TLR6 complex that signals NF-?B 
activation and synthesis of chemokines and pro-IL-1? in macrophages (Stewart 
2010). CD36 recognizes protein adducts of oxidized phospholipids on the surface of 
copper-oxidized LDL (Miller 2011). Furthermore, oxidation by 12/15-lipoxygenase, 
an enzyme present in atherosclerotic lesions, generates ‘minimally modified LDL’ 
that elicits unconventional TLR4 signaling and moderate cytokine and chemokine 
secretion by macrophages (Miller 2012). The TLR4 signaling is mediated by 
cholesteryl ester hydroperoxides generated on the LDL particle (Miller 2011). Of 
note, the proinflammatory effects of oxidatively modified LDL and the oxidized 
components thereof are not limited to macrophages; these species can also trigger the 
expression of chemokines (e.g. monocyte chemotactic protein 1 (MCP-1)), growth 
factors (e.g. M-CSF), and adhesion molecules (e.g. vascular cell adhesion molecule 1 
(VCAM-1)) on cultured human aortic endothelial cells and SMCs (Cushing 1990, 
Rajavashisth 1990, Leitinger 1999). 
Taken together, LDL, the major etiological agent of atherosclerosis, exerts its 
effects on arterial wall cells by promoting both lipid accumulation and inflammatory 
activation, the key drivers of plaque development. The importance of LDL in 
atherogenesis is underscored by the success story of LDL-lowering statins in the 
treatment of atherosclerosis and cardiovascular disease. Statins block cholesterol 
biosynthesis in the liver by inhibiting the rate-limiting enzyme of the pathway, 
3-hydroxy-3-methylglutaryl coenzyme A reductase (Brown 1986). This results in 
enhanced expression of LDL receptors in the liver, promoting more efficient clearance 
of LDL from circulation.
2.3.1.3 HDL promotes reverse cholesterol transport from macrophage foam cells
HDL comprises a heterogeneous group of 7-13 nm lipoprotein particles originating 
from the liver or the small intestine (Toth 2013). The major protein component of 
HDL particles, apoAI, lacks the positive charge clusters found in apoB-100. This 
allows the HDL particles to diffuse more freely through the intima, facilitating 
their exit through the lymphatics in media and adventitia. Importantly, on their way 
through the intima, the HDL particles accept excess cholesterol from the macrophage 
foam cells and transport it via circulation back to the liver for excretion in bile. The 
process is called ‘reverse cholesterol transport’ and it is the major antiatherogenic role 
assigned to HDL (Rosenson 2012). The transfer of cholesterol from lipid-loaded 
macrophages to HDL is mediated actively via ATP-binding cassette transporters A1 
and G1 on the donor cell membrane, and via passive bidirectional transfer through 
SR-B1 and diffusion (Adorni 2007, Larrede 2009). Finally, the HDL is taken up by 
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the liver via direct SR-B1-mediated uptake or indirectly via cholesteryl ester transfer 
protein -mediated transfer to apoB-containing lipoproteins (Rosenson 2012). 
Notably, HDL particles have also numerous anti-inflammatory, antioxidant, 
and antithrombotic effects that are particularly important for the functioning of 
the vascular endothelium (Rosenson 2013). Despite the wealth of data showing 
antiatherogenic functions of HDL, clinical trials have failed to show improved 
cardiovascular outcomes by pharmacological treatments that elevate plasma 
concentration of HDL cholesterol (Toth 2013). These unexpected negative results 
have led to the conclusion that, rather than concentration of HDL cholesterol, the 
antiatherogenic functionality of the HDL particles is the key factor underlying their 
protective effects against cardiovascular disease, a concept now at the focus of HDL 
research (Rosenson 2013).
2.3.2 Stages of atherosclerotic lesion development
The highly complex process of atherosclerotic plaque development, occurring over 
decades in humans, has made the study of this process challenging. The consecutive 
morphological stages of atherosclerotic lesion development were detailed in a series 
of seminal papers published in the 1990’s by a committee set up by the American 
Heart Association (AHA) (Stary 1992, Stary 1994, Stary 1995). The resulting, widely 
used AHA classification of lesions to types I-VI is based on careful examination of 
autopsy samples from patients of different ages and disease stages (Fig. 6).
2.3.2.1 Early stages of atherosclerotic lesion development
The subendothelial retention of LDL in the intima precedes the appearance of first 
isolated macrophage foam cells (Williams 1995), which, in turn, is considered the 
earliest stage of lesion development designated as type I lesion (Stary 1994). As 
discussed in section 2.3.1, modification of the LDL particles in situ in the arterial 
wall drives the SR-mediated uptake of LDL into resident macrophages, as well 
as inflammatory activation of the macrophages and other arterial wall cells. These 
early events promote increased expression of leukocyte adhesion molecules on the 
arterial endothelium and the recruitment of immune cells, chiefly monocytes, into 
the intima. The recruited monocytes differentiate into lipid-scavenging macrophages, 
generating multiple layers of foam cells that form a ‘fatty streak’, or type II lesion 
(Stary 1994). Cholesterol in the fatty streaks accumulates almost exclusively as 
intracellular cholesteryl esters in the foam cells, with very little extracellular lipid. 
Moreover, the intimal SMCs markedly contribute to lipid uptake and foam cell 
formation, and switch from a contractile to synthetic phenotype with enhanced 
production of extracellular matrix components (Stary 1994). Continued lipid 
accumulation yields scattered extracellular lipid deposits in the deep musculoelastic 
intima, and small cholesterol monohydrate crystals begin to appear in the lesions 
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(Stary 1994, Small 1988). These type III lesions are the last in the series of clinically 
silent early lesions and also the precursor for more advanced, symptomatic lesions.
2.3.2.2 Advanced stages of atherosclerotic lesion development
Advanced, type IV-VI lesions are defined as lesions causing marked disruption of 
the normal structural organization of the arterial wall (Stary 1995). The hallmark of 
a type IV lesion is the appearance of a large, continuous pool of extracellular lipid, 
‘the lipid core’, in the deep intima. This is accompanied by a dramatic increase in 
the number and size of cholesterol crystals, found in the core areas of virtually all 
type IV lesions (Small 1988). Crystallization can be predicted from the plaque lipid 
composition; type IV lesions are oversaturated in free cholesterol, overwhelming the 
solubilizing capacity of phospholipids in cellular membranes and extracellular lipid 
pools (Small 1988). Cholesterol crystals are readily nucleated within lysosomes of 
cholesterol-loaded cultured macrophage foam cells (Tangirala 1994, Kellner-Weibel 
1999). Moreover, in human atherosclerotic lesions with an emerging lipid core, 
cholesterol crystals frequently appear within the lipid deposits of deep intima that 
Figure 6. Stages of atherosclerotic lesion development according to the classiﬁcation 
by the American Heart Association. A schematic view of lesion development in a cross-
section of an artery. The vessel lumen is represented by the white space in the center. Note 
the adaptive intimal thickening at the lesion-prone site already in the initial type I lesion. Type 
I-III lesions are clinically silent early lesions, whereas type IV-VI represent advanced plaques that 
may cause clinical manifestations. Adapted from the reports by the Committee on Vascular 
Lesions of the Council on Arteriosclerosis of the American Heart Association (Stary 1994, Stary 
1995). See the text for details.
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is sparse in cells (Bocan 1986). Thus, nucleation of cholesterol crystals in vivo may 
occur both intra- and extracellularly.
SMC proliferation and matrix production leads to the formation of a fibrous cap 
between the lipid core and endothelium, which is considered to exert a protective 
effect against plaque rupture (Stary 1995). Fibrotic responses in the presence or 
absence of a lipid core, accompanied by calcification and stenosis of the vessel lumen, 
characterize type V lesions. Finally, the appearance of leaky neovessels within the 
intima and various endothelial defects at the luminal surface of advanced type IV/V 
lesions may cause haemorrhage and microthrombi that characterize type VI lesions 
(Stary 1995). The advanced plaques may narrow the luminal space and restrict the 
blood flow, or rupture into the vessel lumen, causing a large thrombus and acute 
complications. Myocardial infarction is caused by an occluding thrombus in the 
coronary artery tree, whereas stroke is typically caused by a non-occluding thrombus 
at a carotid artery that results in cerebral embolism. 
The local microenvironment in the advanced lesions becomes progressively hostile. 
The growing plaque mass hinders diffusion of oxygen to the plaque core, creating a 
hypoxic zone in the deep intima (Leppänen 2006, Sluimer 2008). Hypoxia promotes 
anaerobic glycolytic metabolism in the arterial wall cells, resulting in increased 
glucose consumption and lactate production in the deep intima (Leppänen 2006). 
Moreover, macrophage activation involves a switch to glycolytic metabolism even 
under normoxia and thus, macrophages promote increased production of metabolic 
acid and lactate independently of hypoxia (Rodriguez-Prados 2010, Tannahill 2013, 
Roiniotis 2009). Indeed, advanced human carotid plaques exhibit marked deviations 
from the normal physiological pH of 7.4 (Naghavi 2002). The local acidosis of 
extracellular fluids in the plaques reaches approximately pH 6.8-6.0, as measured by 
pH electrodes and pH-sensitive fluorescent dyes (Naghavi 2002). 
2.3.3 Role of immune cells and inﬂammatory mediators in plaque 
development
2.3.3.1 The immune cell population in atherosclerotic lesions
A dynamic population of innate and adaptive immune cells exists in the arterial 
wall throughout the stages of atherosclerotic lesion development. Recent studies 
have shown that the areas of adaptive intimal thickening develop a much denser 
subendothelial network of resident macrophages/dendritic cells compared to the 
adjacent areas (Randolph 2014). This implies that also enhanced immune surveillance 
may contribute to the high susceptibility of these sites to atherosclerosis. The 
continued recruitment of immune cells to the developing lesion greatly amplifies 
the initial inflammatory reaction and profoundly alters the metabolism of the 
resident arterial wall cells. Monocyte-derived macrophages are the most abundant 
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immune cells in atherosclerotic plaques and the nexus between lipid accumulation 
and inflammation. Furthermore, the plaques harbour also abundant T cells and 
dendritic cells, as well as some mast cells and neutrophils (Hansson 2011) (Fig. 7).
Notably, immune cell infiltrates are found not only within the intimal plaque, but 
also in the adventitia adjacent to advanced human plaques (Houtkamp 2001). These 
adventitial infiltrates have an organized structure resembling lymphoid follicles, 
implying local maturation of B cells and generation of humoral immune responses 
(Houtkamp 2001). The development of these so-called tertiary lymphoid organs 
(TLO) is closely linked with chronic inflammation in various diseases, yet their 
functions remain poorly defined (Mohanta 2014). In aged atherosclerotic mice, the 
TLOs comprise activated B cell follicles, a separate T cell area, antigen-presenting 
Figure 7. Organization of immune cells in atherosclerotic lesions. Macrophages and 
other immune cells are particularly abundant at the plaque shoulder regions ﬂanking the lipid 
core. Both macrophages and smooth muscle cells are transformed into lipid-loaded foam cells 
in the intima. The lipid core consists of cell remnants and lipid droplets released from the 
dying cells, modiﬁed and aggregated lipoproteins, and cholesterol crystals. The media adjacent 
to advanced plaques becomes disordered and secretes chemokines that contribute to the 
formation of tertiary lymphoid organs in the adventitia. EC, endothelial cell; SMC, smooth 
muscle cell; DC, dendritic cell; MC, mast cell.
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cells, and plasma cells, implying local activation and proliferation of adaptive immune 
cells (Mohanta 2014, Grabner 2009). Furthermore, medial SMCs underlying the 
intimal plaque were activated to secrete chemokines required in the TLO formation, 
suggesting the existence of a defined relay mechanism of inflammatory signals from 
the intima to the adventitia.
2.3.3.2 Triggers of inﬂammation in atherosclerotic plaques
Oxidized LDL has been suggested as the key agent triggering inflammatory 
responses, as well as foam cell formation, in the arterial wall (Hansson 2011, Miller 
2011). However, dietary supplementation with antioxidants has failed to show 
protection against cardiovascular disease in numerous clinical trials (Tinkel 2012). 
One proposed explanation is that the critical role of oxLDL could be restricted 
to early stages of atherogenesis, rendering antioxidants powerless in patients with 
established atherosclerosis (Tedgui 2006). Nevertheless, only the advanced plaques 
present symptoms in humans. Heat shock proteins and other danger signals released 
from dying cells, diabetes-associated advanced glycation end products, and obesity-
associated adipokines, among others, have been proposed as potential secondary 
drivers that maintain the chronic inflammation in the plaques (Tedgui 2006). 
Also defective resolution of inflammation plays a major role (Tabas 2010). Thus, 
plaque inflammation is exacerbated by the failure to suppress further immune cell 
recruitment, to clear apoptotic cells, and to induce immune cell egress. Notably, 
microbes and their components, such as bacterial DNA, are found in the arterial 
intima, where they could conceivably trigger inflammation (Lehtiniemi 2005, 
Ott 2006). However, based on experiments in germ-free mice, microbial presence 
(bacterial, viral, and fungal) is dispensable for lesion development, and treatment of 
patients with antibiotics showed no protection from cardiovascular events (Tedgui 
2006, Wright 2000). Taken together, despite intensive research in the area, the 
mechanisms triggering and maintaining chronic inflammation during atherogenesis 
remain incompletely understood. 
2.3.3.3 Cytokines and chemokines
The inflammatory activation in human plaques is marked by the immunoreactivity for 
numerous inflammatory cytokines, including for example IFN-?, TNF-?, IL-1?/?? 
IL-2, IL-6, IL-8, IL-10, IL-18, and TGF-? (Frostegard 1999, Ait-Oufella 2011). 
In general, pro- and anti-inflammatory cytokines exert pro- and antiatherogenic 
effects, respectively, in cultured cells and animal models, affirming the major role of 
inflammation in lesion development (Tedgui 2006, Ait-Oufella 2011).  Furthermore, 
a wide selection of chemokines and their receptors are implicated in atherogenesis 
(e.g. MCP-1/CCR2, fractalkine/CX3CR1, RANTES/CCR5), and the vast majority 
of these mediate monocyte trafficking into the lesions (Rolin 2014). 
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Certain cytokines, including IL-1?/?, can further induce their own production 
and the production several other inflammatory mediators to amplify the inflammatory 
response (Dinarello 2009). Furthermore, cytokines can directly activate newly recruited 
immune cells and regulate their polarization state in the lesions (Ait-Oufella 2011). 
Importantly, proinflammatory cytokines trigger diverse responses in the vascular wall 
cells, including oxidative stress, decreased expression of cholesterol efflux receptors 
(IL-1?, IFN-?), increased expression of scavenger receptors (TNF-?, IFN-?), 
induction of leukocyte adhesion molecules and chemokines (IL-1?/?, TNF-?, 
IFN-?, IL-18), suppression of antithrombotic properties of the endothelium (IL-
1?/?, TNF-?), loosening of endothelial tight junctions (IFN-?, TNF-?), suppression 
of SMC collagen synthesis (IFN-?), production of matrix-degrading enzymes (IL-
1?/?? TNF-?, IL-18), induction of neovessel formation (IL-1?, TNF-?), and, 
ultimately, apoptosis (IL-1?/?, TNF-?, IFN-?) (Tedgui 2006, Ait-Oufella 2011, 
Gerdes 2002). Anti-inflammatory cytokines tend to counteract these effects. For 
example, IL-10 and TGF-? inhibit the production of matrix-degrading enzymes 
and promote the expression of cholesterol efflux receptors, and IL-10 also blocks 
neoangiogenesis as well as reduces the production of proinflammatory cytokines 
(Tedgui 2006, Ait-Oufella 2011).
2.3.3.4 Other effectors contributed by immune cells
The immune cells are not only a major source for proinflammatory mediators, 
but release proteolytic and lipolytic enzymes and ROS that modify lipoproteins, 
promoting foam cell formation (Öörni 2000). Furthermore, macrophages, mast 
cells, and neutrophils secrete numerous proteases that degrade extracellular matrix 
(e.g. chymase, tryptase, cathepsins, and metalloproteases) and weaken the fibrous 
cap, promoting plaque rupture (Newby 2014). Indeed, immune cell infiltrates 
with macrophages and activated mast cells are prominent at the immediate site of 
plaque rupture or erosion (Moreno 1994, Kovanen 1995, Kaartinen 1998, Willems 
2013, Howard 2015). Moreover, their presence correlates with the severity of 
cardiovascular symptoms and predicts future cardiovascular events. Finally, immune 
cells contribute to the production of lipid mediators that modulate vascular tone, 
platelet aggregation, and leukocyte adhesion and migration. Lesional macrophages 
are a prominent source of the proatherogenic eicosanoid leukotriene B4, acting as a 
chemoattractant for monocytes and T cells (Hansson 2011). Also activated mast cells 
produce eicosanoids, including prostaglandin D2 and leukotriene B4 (Boyce 2007).
2.3.3.5 Macrophages and innate immune signaling in atherosclerosis
Majority of our knowledge related to the functional role of inflammation in 
atherogenesis is derived from mouse models. The models most frequently used are the 
LDLR-KO mice (Ishibashi 1993), resembling human familial hypercholesterolemia, 
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and the apoE-KO mice (Zhang 1992) exhibiting impaired clearance of VLDL 
and chylomicrons by the liver. Homozygous LDLR- and apoE-KO mice exhibit 
moderate increases in plasma cholesterol and a shift in the lipoprotein profile from 
HDL to high levels of VLDL, IDL, and LDL. These mice spontaneously develop 
early atherosclerotic plaques in the aortic arch, yet a high-fat high-cholesterol 
diet (HFD) induces a rapid development of more advanced lesions in both mouse 
models.
M-CSF-null mice exhibit severely diminished populations of blood monocytes 
and tissue macrophages (Wiktor-Jedrzejczak 1992). Crossing these mice with apoE-
KO mice resulted in 86 % reduction in atherosclerotic lesion area, despite a 3-fold 
higher plasma cholesterol in the M-CSF-null/apoE-KO mice (Smith 1995). These 
findings were later confirmed in a similar study (Qiao 1997). These data verified 
an essential role for macrophages in atherogenesis. In agreement, genetic ablation 
of the chemokine MCP-1 or its receptor CCR2 - the major pathway of monocyte 
recruitment into the arterial wall - markedly reduces atherogenesis in mouse models 
(Gu 1998, Boring 1998). The polarization of macrophages in atherosclerotic plaques 
seems highly adaptive to the immediate microenvironment (Chistiakov 2015). Thus, 
macrophages display a spectrum of different phenotypes, and M1- and M2-like 
phenotypes may localize to distinct niches. 
Numerous studies have reported a role for innate immune activation in 
atherogenesis. TLR expression is low in healthy human arterial walls, yet strong TLR2 
and TLR4 staining was found in macrophages and endothelial cells of atherosclerotic 
plaques (Xu 2001, Edfeldt 2002). Moreover, marked reductions in atherosclerotic 
lesion area and macrophage numbers were demonstrated both in TLR2/LDLR-
dKO and in TLR4/apoE-dKO mice (Mullick 2008, Michelsen 2004). Intriguingly, 
deficiency in the essential LPS co-receptor, CD14, had no effect on atherogenesis 
in apoE-KO mice, implying that microbial ligands were not required for lesional 
TLR4 signaling (Bjorkbacka 2004). Moreover, deficiency in any single component 
of the CD36:TLR4:TLR6 signaling complex, inducible in macrophages by oxLDL, 
markedly reduced plaque area and inflammatory markers in apoE-KO mice (Sheedy 
2013). Finally, deficiency in the Toll/IL-1 signaling adapter MyD88 strongly reduced 
lesion area, as well as macrophage numbers and chemokine expression in the lesions of 
apoE-KO mice (Michelsen 2004, Bjorkbacka 2004). A severely impaired chemokine 
production in response to IL-1? or IL-18 was further demonstrated in MyD88-KO 
mouse macrophages (Bjorkbacka 2004). Collectively, these data suggest an important 
role for innate immune responses in atherosclerosis. 
2.3.3.6 Inﬂammasome target cytokines
In atherosclerotic plaques, macrophages are without a doubt the most prominent 
cells competent in inflammasome signaling and robust cytokine secretion. IL-1? 
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immunoreactivity was detected in macrophage foam cells and endothelial cells of 
human coronary artery and carotid plaques, but not in healthy arteries (Frostegard 
1999, Galea 1996). The amount of IL-1? in the vessel wall correlated with the 
severity of coronary atherosclerosis (Galea 1996). Similarly, immunoreactivity for 
IL-18 was detected in macrophages of human carotid plaques, but not in healthy 
aorta (Gerdes 2002, Mallat 2001a). Moreover, the cleaved, active form of IL-18 
and abundant IL-18 receptor?  were found in the plaques, but not in healthy aorta. 
Finally, IL-18 mRNA was more abundant in unstable compared to stable plaques 
(Mallat 2001a).
Both IL-1? and IL-1? signal through the IL-1 receptor I that is blocked by 
IL-1 receptor antagonist (IL-1Ra) (see section 2.2.3). Subcutaneous administration 
or overexpression of IL-1Ra, as well as deficiency in IL-1 receptor I reduces 
atherosclerotic lesion area in apoE-KO mice by ~50-80 % (Elhage 1998, Merhi-
Soussi 2005, Chi 2004). Both IL-1? and IL-1? contribute to the effects of IL-1 
signaling in atherosclerosis, as deficiency in either cytokine markedly reduces lesion 
development in apoE-KO mice (Kirii 2003, Kamari 2011). Thus, both IL-1?/
apoE-dKO and IL-1?/apoE-dKO mice showed ~50 % reduction in lesion area, 
and similar results were obtained when apoE-KO mice were transplanted with IL-
1?- or IL-1?-KO bone marrow (Kamari 2011). The attenuation of atherogenesis in 
IL-1?-KO mice correlated with reduced aortic expression of VCAM-1 and MCP-1 
(Kirii 2003). Importantly, treatment of rheumatoid arthritis patients with IL-1Ra 
markedly improved vascular and left ventricular function, as assessed by endothelium-
dependent dilation of the brachial artery and by echocardiography, respectively 
(Ikonomidis 2008). Moreover, the plasma levels of IL-1 downstream targets, IL-6 
and the vasoconstrictor endothelin-1, were reduced after IL-1Ra treatment. 
Also IL-18 exhibits clear proatherogenic effects. Neutralization of IL-18 activity 
by IL-18 binding protein markedly reduced lesion development in aorta of apoE-KO 
mice (Mallat 2001b). Moreover, there was a striking change in the plaque composition 
towards increased stability, as assessed by increased collagen content and reduced 
immune cell infiltration. Likewise, lesion development was significantly attenuated 
in IL-18/apoE-dKO mice, despite elevated cholesterol levels caused by the IL-18 
deficency (Elhage 2003). Moreover, the lesions of IL-18/apoE-dKO mice displayed 
reduced markers of IFN-? activity, linking IL-18 with induction of IFN-? in vivo. 
A very recent publication by Wang et al. gave a new perspective to IL-18 signaling 
in atherosclerosis (Wang 2015). It was shown that the IL-18 receptor interacts with 
Na-Cl co-transporter SLC12A3 strongly induced in atherosclerotic arterial wall, 
and that knocking out both IL-18 receptor and SLC12A3, but not either one of 
the molecules alone, attenuates atherosclerosis in apoE-KO mice (Wang 2015). The 
effect was attributed to receptor deficiency in bone marrow –derived leukocytes, and 
the expression of either IL-18 receptor or SLC12A3 was sufficient to trigger cellular 
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IL-18 signaling and IL-18-mediated cytokine production in macrophages and T 
cells (Wang 2015). Thus, cellular ion fluxes and cell volume regulation involved in 
NLRP3 inflammasome activation (Perregaux 1994, Perregaux 1996, Compan 2012, 
Petrilli 2007, Munoz-Planillo 2013, Perregaux 1998, Schorn 2010, Murakami 2012, 
Rabolli 2014) may also contribute to downstream signaling by the inflammasome 
target cytokine IL-18. 
2.3.3.7 Adaptive immune responses in atherosclerosis
Majority of the T cells found in human atherosclerotic plaques are CD4+ T helper 
cells, and a significant proportion of them bear markers of activation (class II HLA, 
IFN-?) (Hansson 1989). Moreover, human plaques, but not peripheral blood, harbour 
CD4+ T cell clones that proliferate and secrete the classical Th1 cytokine IFN-? 
when exposed to monocytes presenting oxLDL-derived antigens (Stemme 1995). 
These data suggest the presence of a local oxLDL-driven autoimmune response 
in human plaques. In agreement, adoptive transfer of oxLDL-reactive CD4+ T 
cells to apoE-KO mice accelerates atherosclerosis (Zhou 2006). Moreover, IFN-? 
receptor/apoE-dKO mice have strongly reduced lesion development, implying 
a proatherogenic role for T cell activation (Gupta 1997). Dendritic cells readily 
migrate from atherosclerotic plaques to the draining lymph nodes, where they 
present plaque-derived antigens to naïve T lymphocytes to activate them (Hansson 
2011). In apoE-KO and LDLR-KO mice, dendritic cells significantly contribute 
to T cell activation and generation of Th1 responses via MHC II-restricted antigen 
presentation (Gautier 2009, Sage 2014). 
OxLDL elicits also humoral immune responses that exert atheroprotective 
effects. Autoantibodies reactive to oxLDL are found in human and rabbit plasma, 
and immunization with oxLDL or native LDL reduces atherogenesis in animal 
models (Hansson 2011, Palinski 1989, Palinski 1995). Both T cell-dependent IgG 
antibodies and T cell-independent natural IgM antibodies are produced against 
oxLDL (Hansson 2011). Moreover, splenectomy aggravates atherogenesis, and 
transfer of splenic B cells from old apoE-KO mice with established atherosclerosis 
into young apoE-KO mice attenuates lesion development via elevating oxLDL 
antibody titers (Caligiuri 2002). 
Surprisingly, lymphocyte-deficient Rag-1- or Rag-2-null mice crossed with 
apoE- or LDLR-KO mice suggest only a minor or transient role for T and B cells 
in atherogenesis (Dansky 1997, Daugherty 1997, Song 2001). In these experiments, 
atherosclerotic lesion area is transiently reduced in early fatty streak lesions of mice 
on chow or HFD, but the difference is lost upon continued HFD resulting in more 
advanced lipid core lesions. In line with these data, proinflammatory Th1 type 
responses and IFN-? production in the lesions dominate in chow-fed apoE-KO 
mice, whereas a clear switch to antibody-associated Th2 type responses and IL-4 
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production is found in apoE-KO mice on HFD (Zhou 1998). Moreover, attenuation 
of Th1 responses in atherosclerotic mice markedly reduces early lesion development 
and boosts the production of antiatherogenic oxLDL antibodies (Laurat 2001, Buono 
2005). Thus, the effect of T cells on atherogenesis is dependent on disease stage and 
T helper cell polarization. Whereas the Th1 subset has a clear proatherogenic role, 
studies on the Th2 and Th17 subsets have yielded mixed results (Hansson 2011). 
Conversely, regulatory T cells (Tregs) that suppress the activity of effector T cells 
have been shown to exert atheroprotective effects (Hansson 2011). Depletion of 
both the naturally arising CD4+CD25+ Treg population and the Tregs positive for 
the lineage marker FOXP3 promotes atherosclerotic plaque development, albeit via 
different mechanisms (Ait-Oufella 2006, Klingenberg 2013). 
In contrast to the combined depletion of T and B cells, the specific depletion 
of B cells in LDLR-KO mice moderately increases atherogenesis, in line with the 
protective effects of oxLDL antibodies (Major 2002). However, more recent data 
suggests that similar to T cells, B cells may display both pro- and antiatherogenic 
effects depending on the B cell subset. Thus, depletion of mature B2 cells using a 
CD20 antibody reduces atherogenesis via limiting T cell responses (Ait-Oufella 
2010). Conversely, adoptive transfer of B1 cells into splenectomized apoE-KO 
mice is atheroprotective (Kyaw 2011). The critical determinant in B1 cell-mediated 
atheroprotection is the production of natural IgM antibodies against oxLDL. In 
agreement, the depletion of B2 cells preserved anti-oxLDL IgM levels while reducing 
only the anti-oxLDL IgG (Ait-Oufella 2010).
To conclude, both innate and adaptive immune responses have a marked impact 
on the development of atherosclerotic lesions. Whereas innate immune activation 
seems to exert mainly proatherogenic effects, the effects of adaptive immune responses 
strongly depend on the balance between different T and B cell subsets (Fig. 8). OxLDL 
and its various components have gained much attention as the potential autoantigens 
triggering innate and adaptive immune responses in atherosclerosis, yet many other 
potential autoantigens have been proposed (Shah 2014). While passive immunization 
with anti-oxLDL antibodies has failed to show atheroprotective effects in clinical 
studies, active vaccination against LDL is a promising immunomodulatory strategy 
to combat atherosclerosis (Shah 2014). However, a major challenge in designing 
practical prototypes of atherosclerosis vaccines is the identification of the specific 
antigens on LDL that trigger atheroprotective immunity (Shah 2014). Other current 
approaches to target atherosclerotic inflammation in clinical trials include a more 
generalized anti-inflammatory treatment with low-dose methotrexate (Everett 2013), 
as well as neutralization of specific inflammatory mediators strongly associated with 
atherogenesis (Ridker 2011). The outcomes of these first large phase III clinical trials 
will lead the way in determining whether inflammation, alongside hyperlipidemia, 
truly is a feasible treatment target for atherosclerosis and cardiovascular disease.
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Figure 8. Summary of immune cell involvement in atherosclerosis. The solid arrows 
denote proatherogenic effects, the T-shaped lines denote antiatherogenic effects, and the 
dashed arrows indicate mixed results. See the details in text. Ag, antigen; HLA II, type II 
human leukocyte antigen; IFN, interferon; IL, interleukin; ROS, reactive oxygen species; TGF-?, 
transforming growth factor ?; TNF-?, tumor necrosis factor ?.
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3 AIMS OF THE STUDY
Inflammation is today recognized as a major driving force in atherogenesis, yet our 
understanding of the specific mechanisms triggering and maintaining inflammation 
in the arterial wall is incomplete. The purpose of this study was to examine the 
potential role of the inflammasome pathway in the pathogenesis of atherosclerosis. The 
proatherogenic effects of the inflammasome-controlled cytokines, IL-1? and -18, are 
well documented, but the triggers for secretion of these cytokines in atherosclerotic 
plaques have remained unknown. Macrophages are the canonical inflammasome 
pathway-competent cells, and also the key immune cells in atherosclerotic lesions. 
Thus, cultured human macrophages offered a highly relevant cell model for the 
screening of candidate inflammasome activators associated with atherogenesis. In 
particular, we were interested in the NLRP3 inflammasome emerging as a mediator of 
sterile inflammatory responses to endogenous danger signals. Furthermore, a unique 
collection of human coronary artery specimens with varying stages of atherosclerosis 
was available at the Wihuri Research Institute. This specimen collection offered 
the opportunity to study the expression of the inflammasome pathway in coronary 
arterial wall, a site most crucial to the acute complications of atherosclerosis. 
The specific aims of this study were: 
1) to identify atherosclerosis-associated endogenous danger signals that activate the 
inflammasome pathway and interleukin-1? and -18 secretion in cultured human 
macrophages, 
2) to characterize in detail the molecular mechanisms mediating the inflammasome 
activation, and 
3) to study the expression pattern of inflammasome pathway components and 
regulators in the coronary arterial wall, and to identify potential changes in the 
expression pattern during progression of coronary atherosclerosis.
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4 MATERIALS AND METHODS
The materials and methods used in this study are summarized in Table 3. For a 
detailed description of each method, the reader is referred to the original publications 
in this thesis (I, II, III) and to additional references or source materials, as indicated. 
Table 3.
Method Original publications Reference /source
Cell culture and tissue samples
Human peripheral blood monocytes I (Nakanishi 2009)
Human monocyte-derived macrophages I, II, III (Nakanishi 2009)
Monocytic  human  THP-1 cell line I, II (Tsuchiya 1980)
Mouse bone marrow-derived macrophages II
Frozen and formalin-ﬁxed parafﬁn-embedded human 
coronary artery specimens
III
Antibody-based techniques 
Enzyme-linked immunosorbent assays (ELISA) I, II, III R&D Systems
Western blotting I, II, III (Burnette 1981)
Immunohistochemical stainings III
Fluorescence-based techniques
Imaging of lysosomes in live cells using the acridine 
orange dye
I (Traganos 1994)
Imaging of cathepsin B activity in live cells using the 
substrate z-Arg-Arg-cresyl violet
I (Van Noorden 
1997)
Confocal ﬂuorescence/reﬂection microscopy to detect 
intracellular cholesterol crystals
I (Hornung 2008)
Cathepsin B/L activity measurement using the 
substrate z-Phe-Arg-AMC
II (Barrett 1980)
Recording of intracellular pH changes in live cells 
using the ﬂuorescent probe BCECF-AM 
II (Nordstrom 2012)
Manipulation and analysis of gene expression
Gene knock-down by small interfering RNAs I, II (Elbashir 2001)
Quantitative real-time RT-PCR I, II, III (Heid 1996)
RT2 Proﬁler Human Inﬂammasomes PCR array for 
human coronary RNA
III Qiagen
Miscellaneous
Preparation of cholesterol crystals I, II, III (Flynn 1979)
Preparation of monosodium urate crystals II (Scanu 2010)
Design of acidic and basic culture media II (Eagle 1971)
Thin layer chromatography I, II (Lähdesmäki 2009)
Cytotoxicity assay (lactate dehydrogenase) II, III Roche
Limulus amebocyte lysate endotoxin assay I, II, III Lonza
Statistical analyses
Mann-Whitney U test, Wilcoxon test, t-test I, II, III
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5 RESULTS AND DISCUSSION
5.1 IDENTIFICATION OF ATHEROSCLEROSIS-ASSOCIATED 
ACTIVATORS OF THE INFLAMMASOME PATHWAY                         
(I, II, UNPUBLISHED DATA)
5.1.1 Candidate activators of the inﬂammasome pathway in 
atherosclerotic plaques (I, II)
When we first set out to find potential inflammasome pathway activators from 
atherosclerotic lesions, cholesterol crystals (CHC) stood out as the strongest 
candidate. During the preceding years, several reports had identified endogenous 
or exogenous crystalline substances as triggers of the NLRP3 inflammasome in 
macrophages (Martinon 2006, Hornung 2008, Dostert 2008). In particular, we were 
intrigued by the gout-associated monosodium urate crystals, the first endogenously 
formed crystals shown to trigger a sterile NLRP3-mediated inflammatory response 
(Martinon 2006). CHC have been acknowledged as a hallmark of advanced 
atherosclerotic lesions since the very earliest studies on atherosclerosis (Virchow 
1863). However, they were considered as an inert material in the lesions and largely 
ignored in the mechanistic studies of disease pathology. 
Interest in another candidate activator of the inflammasome pathway arose 
from the earlier studies on extracellular acidosis and lipoprotein modification at the 
Wihuri Research Institute (Lähdesmäki 2009). Elevated lactate concentrations and 
local acidification of the extracellular fluids have been demonstrated in the cores 
of advanced human and rabbit atherosclerotic plaques (Leppänen 2006, Naghavi 
2002). In fact, local acidosis is a common characteristic of many acute and chronic 
inflammatory sites (Menkin 1956, Cummings 1966, Treuhaft 1971, Hunt 2000). 
Despite the clear connection between inflammation and local acidosis, studies on 
the effects of low pH on immune cell function are rather limited (Lardner 2001). 
Notably, during acute inflammation, macrophages are resistant to the acidification of 
the inflammatory exudate and are thus able to adapt to survival and function under 
acidic environment (Menkin 1956).
5.1.2 Cholesterol crystals and extracellular acidosis trigger NLRP3 
inﬂammasome activation in macrophages (I, II, unpublished data)
We began our studies by crystallizing pure cholesterol from ethanol (study I) and 
by designing a custom RPMI-based cell culture medium covering the pH range 
7.5-6.0 with a single buffer system (study II). We treated human peripheral blood 
monocytes, primary human monocyte-derived macrophages (MDMs), mouse bone 
marrow–derived macrophages (BMDMs), and phorbol-12-myristate-13-acetate 
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(PMA)-differentiated human THP-1 macrophages with these two candidate 
inflammasome activators. Resting primary monocytes and macrophages express 
low levels of NLRP3 receptor and no pro-IL-1?, and the transcriptional induction 
of both molecules is required for NLRP3 inflammasome assembly and secretion of 
mature IL-1? (Bauernfeind 2009, Puren 1999). In contrast, PMA-differentiation 
induces stable expression of pro-IL-1??(Fenton 1988), as well as markedly enhances 
the expression of NLRP3 receptor (unpublished data) in THP-1 macrophages. 
Secretion of the mature 17 kDa form of IL-1? was used as the primary readout for 
inflammasome activity, as detected by IL-1? (p17)-specific ELISA or by Western 
blotting.
We found that neither CHC nor acidic culture medium triggered IL-1? secretion 
in resting primary human monocytes or MDMs (study I, Fig. 2A-B; study II, stated 
in text). However, when the cells were costimulated (study I) or primed for 4 h 
(study II) with the TLR4 ligand LPS, both CHC and acidic media at pH 6.5-6.0 
triggered dose-dependent secretion of mature IL-1? (study I, Fig. 2A-B; study II, 
Fig. 1A). Similarly, acidic pH triggered IL-1?  secretion in LPS-primed mouse 
BMDMs (Supplemental Fig. S2A). LPS rapidly induced the synthesis of pro-IL-
1? and NLRP3, but not NLRP1, in human MDMs, whereas CHC had little effect 
(study I, Fig. 3A-C). Thus, both CHC and acidic environment specifically induced 
the inflammasome-mediated cleavage step of pro-IL-1? in LPS-primed human 
MDMs, enabling IL-1? secretion. As expected, the THP-1 macrophages showed 
strong, dose-dependent secretion of IL-1? in response to CHC and low pH without 
the requirement for LPS priming (study I, Fig. 2C; study II, Fig. 1B). Also IL-18 
secretion was induced by low pH (study II, Fig. 1C). Notably, the effect of acidic pH 
was fully reversible, as IL-1? secretion was not sustained after incubation of the cells 
at low pH, followed by return to physiological pH (study II, Fig. 5D). 
The caspase-1 inhibitor z-YVAD-fmk markedly attenuated CHC- and low pH-
induced IL-1? secretion in human MDMs and THP-1 macrophages (study I, 
Fig. 4; study II, Fig. 3A, E, and H). Furthermore, caspase-1 activation was directly 
demonstrated by Western blotting in culture supernatants of low pH-treated THP-1 
macrophages that displayed the active 10 kDa caspase-1 subunit at pH 6.5-6.0 (study 
II, Fig. 1D). As described in section 2.2.3, robust activation of caspase-1, particularly 
during bacterial infection, may cause a rapid caspase-1-dependent pyroptotic cell 
death. However, CHC and low pH only slowly triggered cell death of human MDMs, 
as determined by lactate dehydrogenase release into the culture medium (unpublished 
data). For example, over 95 % and ~80 % of LPS-primed human MDMs remained 
viable after 8 and 24 h treatment with a high 2 mg/ml concentration of CHC, 
respectively. Compared to MDMs, the THP-1 macrophages were more susceptible 
to cell death in response to inflammasome activation. Nevertheless, stimulation of 
THP-1 macrophages with acidic medium triggered the release of mature IL-1? at 
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earlier time points than the release of lactate dehydrogenase (study II, Supplemental 
Fig. S2B and C). Thus, IL-1? was actively secreted, rather than passively released 
upon cell death.
We subsequently silenced the expression of the NLRP3 receptor in THP-1 
macrophages using a combination of two small interfering RNAs (siRNAs) (study 
I, Fig. 6A; study II, Fig. 4C). As a result, IL-1? secretion in response to CHC 
(study I, Fig. 6B) and low pH (study II, Fig. 4D) was completely abolished, whereas 
TNF-? secretion was not significantly reduced (study II, Fig. 4E). Thus, CHC and 
extracellular acidosis were identified as novel endogenous danger signals that trigger 
an innate immune response via the NLRP3 inflammasome. 
Both the active and inactive forms of IL-1? and caspase-1 were secreted by THP-
1 macrophages in response to CHC and acidic medium (study I, Fig. 2C inset; study 
II, Fig. 1D). Similarly, we observed low pH-induced secretion of ASC by Western 
blotting (unpublished data). It was recently shown that the whole speck-like NLRP3/
ASC inflammasome complex is secreted from mouse macrophages as an intact 
complex that continues pro-IL-1? processing in extracellular fluids (Baroja-Mazo 
2014, Franklin 2014). Moreover, proteases secreted by neutrophils and mast cells in 
human atherosclerotic lesions (proteinase 3, cathepsin G, chymase) can process IL-
1? extracellularly into an active form (Newby 2014, Coeshott 1999, Hazuda 1990, 
Mizutani 1991). Thus, multiple mechanisms may propagate local production of active 
IL-1? in plaques, promoting chronic inflammation.
5.1.3 Initial events in NLRP3 inﬂammasome activation by cholesterol 
crystals and extracellular acidosis (I, II)
CHC and extracellular acidosis are chemically and physically very different entities 
that both act as NLRP3-activating danger signals. We next explored the underlying 
mechanisms enabling NLRP3 inflammasome activation by these stimuli. While 
cholesterol crystals are subjected to phagocytosis by macrophages (McConathy 
1989), changes in extracellular pH could affect a wide range of cellular functions 
via triggering changes in the behaviour of various biomolecules.
5.1.3.1 Phagocytosis of cholesterol crystals 
Phagocytosis is required for NLRP3 activation by other crystalline and particulate 
stimuli (Hornung 2008, Dostert 2008) and we thus explored phagocytosis as 
the potential first step in CHC-induced inflammasome activation. CHC are 
phagocytosed by cultured macrophages and the cells store some of the crystal-
derived free cholesterol as cholesteryl esters (McConathy 1989). We thus utilized 
the cellular cholesteryl ester content as a marker of CHC phagocytosis. Inhibition of 
CHC phagocytosis by cytochalasin D strongly reduced both intracellular cholesteryl 
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ester accumulation and IL-1? secretion in THP-1 macrophages (study I Fig. 1A 
and B; Fig. 4). Of note, more and more cell-associated crystals accumulated in 
macrophages over time, suggesting that the cells are not able to eliminate the CHC 
by dissolving them. To directly demonstrate phagocytosis of CHC, we employed 
confocal reflection microscopy (Hornung 2008). The ordered crystal structure reflects 
the laser beam back to the detector, which allowed us to visualize CHC in the 
intracellular space, confined within the cholera toxin subunit B-labeled plasma 
membrane (study I, Fig. 1C). In the presence of cytochalasin D, the CHC remained 
extracellular. Taken together, the phagocytotic uptake of CHC is required for CHC-
induced activation of the NLRP3 inflammasome. 
5.1.3.2 Acidic environment causes intracellular acidiﬁcation
Changes in the extracellular pH could, in principle, affect virtually any biomolecule 
at the cell surface or in the surrounding matrix to trigger cellular signaling events. In 
the context of NLRP3 inflammasome activation, acidic pH could conceivably induce 
cellular potassium efflux and/or other disturbances in intracellular ion concentrations. 
Direct sensors of acidosis, the acid-sensing ion channels and the proton-sensing 
G-protein coupled receptors, could modulate cellular ion fluxes directly or via second 
messengers (Deval 2015, Okajima 2013). However, the expression and functionality 
of these molecules in macrophages remains largely unexplored (Okajima 2013, Friese 
2007). Intriguingly, the NLRP3-activating bacterial toxin nigericin is an ionophore 
that mediates electroneutral K+ efflux compensated by H+ influx and intracellular 
acidification (Mariathasan 2006, Perregaux 1994). The K+ efflux, rather than H+ 
influx, is essential for IL-1? secretion. However, the counterbalancing cation influx 
plays an important role, as an electrogenic ionophore inducing only K+ efflux is not 
sufficient to trigger IL-1? maturation and secretion (Perregaux 1994). We thus 
hypothesized that intracellular acidification (i.e. influx of H+) was an essential step 
in NLRP3 inflammasome activation induced by acidic environment. 
To monitor changes in intracellular pH (pHi), we performed live cell imaging using 
the cell-permeable, fluorescent pH indicator dye BCECF-AM (Nordstrom 2012). 
We showed that at extracellular pH (pHe) of 7.5, the pHi in THP-1 macrophages 
was ~7.2 (study II, Fig. 5C), in line with earlier studies (Bidani 1995, Baldini 2003). 
A drop in pHe to 6.5 caused a decrease in pHi to 6.85 within 10 min, which was 
sustained after 3 h of incubation (study II, Fig. 5C and Supplemental Fig. S5B). 
We subsequently blocked the major regulators of macrophage pHi, the V-type H+ 
ATPase and Na+/H+ exchangers (Swallow 1993). These ion pumps/exchangers 
extrude metabolic acid from the cells and their inhibition by bafilomycin A1 and 
5(N-ethyl-N-isopropyl)amiloride results in gradual acidification of macrophage pHi 
(Bidani 1995, Baldini 2003). Exposure of human MDMs or THP-1 macrophages 
to these agents enhanced IL-1? secretion at pHe 6.5 and after prolonged exposure, 
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triggered IL-1? secretion at pHe 7.5 (study II, Fig. 5A and B, Supplemental Fig. 
S5A). These data suggested that a drop in pHi was indeed required for inflammasome 
activation at acidic environment. 
Intriguingly, a marked drop in cytosolic pH is an early event in the intrinsic 
pathway of apoptosis (Gottlieb 1996, Matsuyama 2000). Thus, acidosis in the 
cytosol precedes cytochrome c release from the mitochondria and enhances the 
subsequent cytochrome c-mediated activation of apoptotic caspases in the cytoplasm. 
Cytochrome c triggers caspase activation via the apoptosome complex that exhibits 
marked similarity with the inflammasome complexes in structure, function, and 
regulation (Chai 2014, Gross 2011). Similar to potassium efflux, ROS, and lysosomal 
damage, acidification of the cytosol may thus be a conserved signaling event in 
the assembly of the apoptosis-associated and the inflammation-associated caspase-
activating platforms (Gross 2011). 
5.1.4 Intracellular stress signals mediate the activation of the NLRP3 
inﬂammasome by cholesterol crystals and extracellular acidosis           
(I, II, unpublished data)
After defining the early steps involved in the exposure of macrophages to CHC or 
acidosis, we dissected the roles of the intracellular stress signals previously shown 
to mediate NLRP3 inflammasome activation (described in section 2.2.5). Thus, 
following phagocytosis of many crystalline/particulate NLRP3 activators, lysosomal 
destabilization and release of lysosomal enzymes, cathepsin B in particular, into the 
cytoplasm signals activation of the NLRP3 receptor. Similarly, enhanced production 
of mitochondrial ROS and potassium efflux from cells contribute to activation of 
the NLRP3 receptor, with ensuing assembly of the NLRP3 inflammasome.
5.1.4.1 Lysosomal destabilization and cathepsin B
Silica crystals and fibrillar amyloid-? trigger NLRP3 activation via lysosomal 
swelling, permeabilization, and release of cathepsin B into the cytoplasm (Hornung 
2008, Halle 2008). We thus studied lysosomal integrity in THP-1 macrophages 
treated with CHC or pH 6.5 medium. Acridine orange stain is trapped into acidic 
organelles, where the low pH induces stacking of the dye molecules and a shift 
from green to red fluorescence (Traganos 1994). A typical red, punctate cytoplasmic 
staining corresponding to lysosomes was seen in untreated macrophages, and the 
red signal was markedly diminished in CHC-treated cells, but not in cells treated 
with acidic medium (study I, Fig. 5; study II, Supplemental Fig. S3A). Similarly, 
visualization of cellular cathepsin B activity with a fluorescent substrate showed loss 
of the punctate lysosomal pattern in CHC-treated cells (study I, Fig. 5). Instead, 
large swollen vesicle structures with active cathepsin B and an overall decrease in 
cellular cathepsin B activity were observed, implying release into the cytoplasm with 
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ensuing enzyme inactivation by neutral pH. Finally, CHC-induced IL-1? secretion 
was reduced by ~70 % in the presence of the cathepsin B inhibitor CA-074-Me 
(study I, Fig. 4). As CA-074-Me inhibits both cathepsins B and L, both proteases 
may be involved in the CHC-induced inflammasome activation (Montaser 2002). 
Notably, the expression and activity of cathepsins B and L is increased in the arterial 
wall macrophages during atherogenesis (Chen 2002, Liu 2006).
The normal lysosomal pH is ~4.8 and thus, it was not surprising that the mild 
extracellular acidosis lacked effect on these organelles. However, CA-074-Me weakly 
inhibited low pH-induced caspase-1 activation and IL-1??secretion (study II, Fig. 3C, 
H and I). Additionally, release of active cathepsin B by macrophages was enhanced 
in acidic environment (study II, Supplemental Fig. S3B). Conceivably, the lysosomal 
permeabilization could have been at a stage too early to detect after 3 h at pH 6.5, 
despite the clear IL-1? response (study II, Supplemental Fig. S3A). This would also 
imply that the lysosomal permeabilization was a relatively late, secondary effect in 
low pH-induced inflammasome activation. Notably, human MDMs constitutively 
secrete cathepsins, and increased cathepsin B activity in the acidic medium could 
also reflect the slower inactivation of these proteases at acidic pH (Punturieri 2000). 
5.1.4.2 Reactive oxygen species (ROS) formation
The general ROS inhibitor N-acetyl-L-cysteine (NAC) markedly reduces IL-1? 
secretion in response to various NLRP3 activators (Dostert 2008, Hewinson 2008). 
NAC reacts directly with e.g. hydroxyl radical and hydrogen peroxide and is also a 
precursor for the antioxidant glutathione (Aruoma 1989). We tested a wide range 
of NAC concentrations and treatment modes both in human MDMs and THP-1 
macrophages. However, NAC consistently lacked any effect on CHC- or low pH-
induced IL-1? secretion in human MDMs and in THP-1 macrophages (study II, 
Fig. 3B, unpublished data). In agreement, extracellular and intracellular acidosis 
reduces superoxide levels in LPS- and PMA-treated macrophages (Bidani 1995, 
Swallow 1993). Interestingly, CHC-induced IL-1? secretion is partially blocked in 
NF-E2-related 2 (Nrf2)-deficient macrophages (Freigang 2011). Nrf2 is a potent 
mediator of antioxidant responses, but CHC-induced ROS production or other 
mechanistic aspects were not explored in the study. Thus, the involvement of ROS 
or ROS-detoxifying responses in CHC-induced inflammasome activation warrants 
further studies.
 
5.1.4.3 Potassium efﬂux 
Potassium efflux is an essential prerequisite for the activation of NLRP3 
inflammasome by diverse stimuli (Petrilli 2007, Munoz-Planillo 2013). We showed 
that the CHC- and low pH-induced IL-1??response was highly dependent on K+ 
efflux, both in THP-1 macrophages (study I, Fig. 4; study II, Fig. 3D and H) and 
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in human MDMs (study II, Fig. 3F). This was demonstrated by adding 130 mM 
KCl to the culture medium, which balances the extracellular and intracellular K+ 
concentrations and thereby abolishes the K+ gradient. The release of active cathepsin 
B into the cytoplasm has been linked to K+ efflux during NLRP3 inflammasome 
activation (Munoz-Planillo 2013), which may underlie also the CHC-induced K+ 
efflux. Conversely, low pH is more likely to modulate the activity of cell membrane 
ion channels. Notably, pH modulates the activity of the ATP-gated ion channel 
P2X7 that is known to trigger activation of the NLRP3 inflammasome (Liu 2009). 
However, acidic extracellular pH strongly inhibits the P2X7 receptor-mediated ion 
currents, rather than enhances them. In agreement, preincubation of macrophages 
at neutral pH with the P2X7 receptor antagonists oxidized ATP (Murgia 1993) or 
KN-62 (Baraldi 2003) did not block the low pH-induced IL-1? secretion (study 
II, Fig. S4A and B). Thus, we explored other candidate K+-conducting channels. 
PMA-differentiated THP-1 macrophages express at least two types of outward 
K+ currents: small conductance ‘SK’ and large conductance ‘maxi-K’ type Ca2+-
activated K+ channels (DeCoursey 1996, Kim 1996). Both SK and maxi-K currents 
are blocked by tetraethylammonium, and SK channels are additionally blocked by Cs+ 
and Ba2+. We found significant inhibition of low pH-mediated IL-1? secretion by 
each of these three nonselective K+ channel blockers in THP-1 macrophages, whereas 
4-aminopyridine showed no effect (study II, Fig. 3G). In agreement with our results, 
THP-1 monocytes express a 4-aminopyridine-sensitive delayed rectifier K+ current 
that is lost upon PMA-differentiation of THP-1 macrophages (DeCoursey 1996). 
As the activation of the NLRP3 inflammasome involves intracellular Ca2+ signaling 
(Elliott 2015), the Ca2+-sensitive K+ channels mediating the SK or the Maxi-K 
type currents in THP-1 macrophages could indeed be involved in low pH-induced 
NLRP3 activation. Earlier studies found no effect by the maxi-K channel blocker 
paxilline on NLRP3-mediated caspase-1 activation (Petrilli 2007). However, the SK 
channels remain unexplored in this context. 
5.1.4.4 Summary of NLRP3 activation mechanisms by cholesterol crystals and 
low pH
Taken together, we identified two novel atherosclerosis-associated danger signals 
that trigger a strong inflammatory response via activating the NLRP3 inflammasome 
in human macrophages (Fig. 9). The proatherogenic effects of IL-1? and -18 
have been widely documented (see section 2.3.3), yet the factors triggering their 
secretion in the plaques remained unknown. CHC are a danger signal directly 
arising from the defective lipid metabolism in the arterial wall and crystallization of 
cholesterol may thus link pathological lipid accumulation to chronic inflammatory 
responses. Phagocytosis of CHC, lysosomal permeabilization, release of cathepsin 
B to cytoplasm, and K+ efflux were all essential for CHC-induced IL-1? secretion 
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(study I). While we were finalizing the manuscript, a group led by Prof. Eicke 
Latz published a study describing a highly similar mechanism of CHC-induced 
NLRP3 inflammasome activation in mouse macrophages (Duewell 2010). Thus, 
CHC caused marked lysosomal damage and the CHC-induced IL-1? secretion was 
markedly reduced in cathepsin B or L-deficient cells, and abolished in NLRP3- and 
ASC-deficient cells. As described in chapter 5.2, this highly influential work also 
explored the effects of knocking out NLRP3 inflammasome components in mouse 
models of atherosclerosis. 
Conversely, extracellular acidosis is a danger signal related to hypoxia and the 
chronic activation of macrophages and other immune cells in the arterial wall, 
causing a build-up of metabolic acid similar to other inflammatory sites (Öörni 
2015). Acidic environment caused a drop in the intracellular pH of macrophages, 
which was sufficient to trigger the inflammasome-mediated cytokine response (study 
II). Moreover, K+ efflux was crucial for low pH-induced NLRP3 activation. It seems 
conceivable that the efflux of K+ is triggered to compensate for the electrogenic influx 
of H+ at acidic environment, yet this remains to be proven. Our data suggests that 
the K+ efflux is not mediated by nonspecific loss of membrane integrity, but, instead, 
via opening of as yet unidentified K+ channels at the plasma membrane. 
Figure 9. Summary of NLRP3 activation mechanisms by cholesterol crystals and acidic 
environment. See the text for details. AP-1, activator protein 1; NF-?B, nuclear factor kappa-
light-chain-enhancer of activated B cells; LPS, lipopolysaccharide; TLR, Toll-like receptor.
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5.2 EXPRESSION OF THE INFLAMMASOME PATHWAY IN 
HUMAN ARTERIAL WALL (III)
The first study to explore the effects of knocking out NLRP3 inflammasome 
components in atherogenesis provided persuasive evidence suggesting a 
proatherogenic role for this pathway (Duewell 2010). LDLR-KO mice were 
reconstituted with NLRP3- or ASC-KO bone marrow, or with IL-1?/?-dKO 
bone marrow, and fed a HFD for 8 weeks. Lesion area at the aortic sinus was in 
each case reduced by ~70 % compared to mice receiving wild type bone marrow. 
Serum levels of IL-18 were also significantly decreased. In a study published a year 
later, apoE-KO mice were crossed with NLRP3-, ASC-, or caspase-1-KO mice 
and no alterations in plaque size or composition were observed after 11 weeks of 
HFD (Menu 2011). Two further studies utilizing apoE/caspase-1-dKO mice and 
LDLR-KO mice reconstituted with caspase-1-KO bone marrow showed decreased 
atherosclerotic lesion area and reduced IL-1? locally in the plaques and in plasma 
(Usui 2012, Hendrikx 2015). The underlying causes for these contrasting results 
remain unclear, but differences in the HFD compositions may have played a role. 
Thus, the three studies showing attenuation of atherosclerosis featured 0.15-0.20 
% cholesterol in the HFD (Duewell 2010, Usui 2012, Hendrikx 2015), while 
the report showing no changes featured an 8-fold higher concentration (1.25 %) 
(Menu 2011). The apoE-KO mice used in the latter study are also inherently more 
hypercholesterolemic than LDLR-KO mice (Ishibashi 1993, Zhang 1992). Thus, 
an overwhelmingly high plasma cholesterol level driving rapid and massive lipid 
accumulation could have masked any inflammation-associated effects. 
Meanwhile, data on the role of the inflammasome pathway in human atherosclerosis 
remains scarce. In stark contrast to the rapid lesion development in mice, human 
lesions develop over decades and the advanced plaques acquire much more complex 
and varied morphologies. This prompted us to study the expression of inflammasome 
pathway components and regulators in the atherosclerotic human arterial wall. 
5.2.1 Pathway-focused expression analysis of the inﬂammasome 
pathway in human coronary arteries (III)
To analyse inflammasome pathway expression in human arterial wall, we utilized a 
human coronary artery specimen collection established earlier at the Wihuri Research 
Institute. RNA was isolated from frozen coronary artery specimens obtained from 10 
males, age 49-65 years, exhibiting marked coronary atherosclerosis (sample details 
in study III, Supplemental Table 1). The specimens were collected either during 
heart transplantation surgery or from candidate heart transplants that did not fulfil 
the criteria for clinical use. Two cross-sectional coronary segments were retrieved 
from each patient for RNA isolation (total n=20): a control sample from an early, 
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clinically silent lesion (AHA type I-III; see section 2.3.2) and a sample from an 
advanced atherosclerotic plaque (AHA type IV-VI) (Stary 1994, Stary 1995). All 
arterial wall layers were included in the samples. The setup allowed the comparison of 
early and advanced disease status in a single patient, i.e. the samples had an identical 
genetic background and had been exposed to the same local tissue environment and 
risk factors of atherosclerosis. The expression analysis of the human coronary RNA 
samples was carried out using a commercial, thoroughly validated quantitative PCR 
(qPCR) array targeting 88 inflammasome pathway-related genes. The target genes 
included the core components and regulators of the inflammasome complexes, as 
well as other NLR family proteins, IL-1 family cytokines, and molecules related 
to proinflammatory cytokine expression and signaling (full listing in study III, 
Supplemental Table 2). 
The results of the pathway-focused qPCR array analysis are shown in Table 1 
of Study III. The significant changes in gene expression are shown as fold changes 
of expression in the advanced coronary plaques (AHA IV-VI) compared to the 
early lesions (AHA I-III). Twelve target genes were significantly upregulated in 
the pair-matched comparison of the samples, whereas no genes were significantly 
downregulated. The fold changes were moderate, which was expected due to the 
experimental setup. Indeed, at advanced stages of atherosclerosis, inflammatory cell 
infiltrates are highly prevalent in plaques throughout the coronary tree (Mauriello 
2005). Thus, also the areas free of gross plaques are, to varying degrees, exposed to 
an inflammatory microenvironment. Nevertheless, the stringent comparison to an 
internal control area from the same coronary tree eliminated several confounding 
factors related to inter-person comparisons. These include differences in age (truly 
atherosclerosis-free coronary artery specimens can be retrieved only from young 
children, whereas advanced plaques develop in adults), genetic background, lifestyle, 
medication, and in details of the coronary sample collection procedure.
Among the target genes significantly upregulated in advanced coronary plaques, 
the most consistent changes were found in the expression levels of caspase-1, IL-18, 
p38? MAPK, baculoviral IAP repeat containing 3 (BIRC3), and IL-1Ra (study III, 
Table 1). Furthermore, the universal inflammasome adapter ASC was upregulated, 
and, together with caspase-1 and IL-18, formed a prominent signature of upregulated 
inflammasome pathway core components in the advanced coronary lesions. The 
increased expression of IL-1Ra in advanced plaques compared to early lesions further 
implied ongoing IL-1 signaling in the arterial wall. Moreover, p38 MAP kinases 
are intimately involved in pro-IL-1? synthesis and in IL-1? and IL-18 signaling 
(Arthur 2013, Lee 2004). Finally, the ubiquitin ligase BIRC3 was recently linked 
with regulation of inflammasome activity (Labbe 2011, Vince 2012). 
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The inflammasome-forming AIM2 dsDNA sensor was likewise significantly 
upregulated in advanced coronary plaques compared to early lesions (study III, Table 
1), in agreement with a recent immunohistochemical study in carotid plaques (Hakimi 
2014). AIM2 expression is potently induced by interferon-?, a proatherogenic Th1 
cytokine found in atherosclerotic lesions (DeYoung 1997, Frostegard 1999, Gupta 
1997). Moreover, bacterial DNA has been demonstrated in human coronary lesions 
and could serve as an AIM2 activator (Lehtiniemi 2005, Ott 2006) alongside genomic 
DNA released from dying cells. In addition to the PYHIN family member AIM2, the 
NLR family proteins known to assemble inflammasomes (NLRP1, NLRP3, NLRP6, 
NLRC4 (Strowig 2012)) were all expressed in the coronary artery wall, and of 
these, NLRP6 was significantly upregulated in advanced coronary plaques (study III, 
Supplemental Fig. 1C and Table 1). Also the class II major histocompatibility group 
transactivator (CIITA/NLRA), essential for expression class II HLA molecules and 
thus crucial for antigen presentation (Steimle 1993, Steimle 1994), was upregulated in 
advanced plaques. Finally, we found upregulation of cathepsin B involved in NLRP3 
activation, in agreement with upregulation and activation of cathepsin B in advanced 
aortic lesions of mice (Chen 2002). 
All IL-1 family cytokines were expressed at detectable levels (IL-1? only barely) 
in the coronary lesions, in the order of increasing expression IL-1? < IL-1? < IL-1Ra 
< IL-18 < IL-33 (study III, Supplemental Fig. 1A). Moreover, among the caspases 
targeted by the qPCR array (caspases 1, 5, and 8), caspase-1 was the most abundantly 
expressed (study III, Supplemental Fig. 1B). Among the NLR and PYHIN family 
target genes, NAIP, a ligand sensor for the NLRC4 inflammasome (Yang 2013), 
was by far the most highly expressed, matched by the ASC adapter protein (study 
III, Supplemental Fig. 1C). NLRC4, NLRC5, NLRP1, NLRP3, and NOD1 were 
expressed at an intermediate level; AIM2, CIITA, NLRP6, NLRP9, and NLRX1 
were expressed at a low level; finally, the expression of NLRP4, NLRP5, NLRP12, 
and NOD2 was virtually undetectable.
Taken together, we have defined here the set of inflammasome pathway components 
expressed in human coronary artery wall. Furthermore, we showed upregulation of 
several core components of the inflammasome pathway, including ASC, caspase-1, and 
IL-18, in advanced coronary plaques compared to early lesions from the same coronary 
trees, implying increased activity of the pathway in progression of atherosclerosis.
5.2.2 Immunohistochemical detection of the NLRP3 inﬂammasome 
in human coronary arteries (III)
As the NLRP3 inflammasome had been implicated in atherosclerotic lesion 
development in mouse models, we further studied the expression of the NLRP3 
inflammasome in human atherosclerotic lesions by immunohistochemistry. Similar 
to the setup used in the qPCR array analysis, we compared areas with early coronary 
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lesions to advanced coronary plaques in the same set of 10 male subjects. Formalin-
fixed paraffin-embedded coronary specimens, rather than frozen specimens, were 
utilized owing to their superior morphological features. Adjacent sections were 
stained with antibodies against the NLRP3 receptor, the ASC adapter, the caspase-1 
protease, and the macrophage marker CD163.
Representative results of the immunohistochemical stainings are presented in 
Fig. 1A-C of Study III. Negative control stainings with corresponding nonimmune 
immunoglobulin preparations showed no staining in the coronary arteries or appendix 
(study III, Supplemental Fig. 2A-B). The early coronary lesions exhibited scattered 
groups of intimal, as well as abundant adventitial, CD163+ macrophages (study III, 
Fig. 1A). Occasional ASC+ and caspase-1+ cells with macrophage morphology were 
found in the intima and the adventitia of the early lesions, but NLRP3+ cells were 
extremely rare. In advanced coronary plaques, abundant intimal CD163+ macrophage 
foam cells were found around the lipid cores of the lesions (study III, Fig. 1B and 
C). In addition, extracellular CD163 staining was frequent within and around the 
acellular lipid core, reflecting macrophage cell death. NLRP3+, ASC+, and caspase-1+ 
foam cells were found around the lipid core, with a staining pattern closely resembling 
that of CD163. Strikingly, also extracellular NLRP3 staining was found within 
and around the lipid core, closely resembling the extracellular staining pattern of 
CD163 in adjacent sections (study III, Fig. 1B and C, Supplemental Fig. 2C). The 
strongest staining for the NLRP3 receptor was observed within large lipid cores 
exhibiting abundant cholesterol crystals and macrophages, whereas NLRP3 was 
absent in fibrocalcific plaques with less pronounced macrophage infiltration (study 
III, Supplemental Fig. 2C and D). Thus, the expression of the NLRP3 receptor 
was associated with an inflammatory plaque phenotype and with the presence of 
cholesterol crystals, an established activator of the NLRP3 inflammasome. 
Similar to our results, other studies have found caspase-1+ macrophages near the 
lipid cores of human atherosclerotic plaques, where they colocalized with apoptotic 
and glycolytic markers, as well as with IL-1? (Geng 1995, Folco 2014). Of note, 
enhanced glycolysis at the sites of caspase-1 expression implies metabolic acid 
production and exposure of the macrophages to fluctuations in pH. Interestingly, 
the expression pattern of the AIM2 receptor in human carotid arteries (Hakimi 
2014) markedly differs from that of NLRP3, ASC, and caspase-1 in human coronary 
arteries observed in Study III. Thus, AIM2 is strongly expressed in healthy carotid 
arteries, in the endothelial cells of luminal endothelium and vasa vasorum, as well as 
in vascular smooth muscle cells. Moreover, in carotid plaques, both smooth muscle 
cells and macrophages surrounding the plaque lipid cores express AIM2 (Hakimi 
2014). The strong expression of AIM2 in non-immune cells of the healthy arterial 
wall implies functions divergent from the NLRP3 receptor that was exclusively 
expressed in macrophages and only in advanced plaques with a marked lipid core. 
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5.2.3 p38? MAPK – a novel effector in NLRP3 inﬂammasome 
activation (III)
The p38? MAPK was among the qPCR array targets most consistently upregulated 
in advanced human coronary plaques compared to early lesions (study III, Table1). 
Moreover, p38? was the only MAPK upregulated in the panel of 8 MAPKs in the 
array, which also included p38??and p38??MAPKs (study III, Supplemental Table 2).
5.2.3.1 The functions of p38? MAPK in inﬂammation remain largely unknown
The p38 MAPKs are serine/threonine protein kinases that are activated by upstream 
MAPK kinases 3, 4, and 6 via dual phosphorylation of conserved threonine and 
tyrosine residues (Cuadrado 2010). The p38 MAPK family plays an important 
role in TLR-mediated proinflammatory cytokine expression, including pro-IL-1? 
synthesis, as well as in signaling elicited by the IL-1 and IL-18 receptors (Arthur 
2013, Lee 2004). Thus, the p38 MAPKs contribute to inflammasome priming and 
to downstream signaling by the inflammasome target cytokines. However, the role 
of p38 MAPKs in inflammation and in proinflammatory cytokine expression has 
been mainly attributed to the ubiquitous p38? isoform (Arthur 2013, Cuadrado 
2010). The other p38 isoforms (?, ?, and ?) have more restricted expression patterns, 
implying specialized functions (Arthur 2013, Cuadrado 2010). Very few studies 
have explored the role of p38??MAPK in the context of inflammation. However, the 
p38? MAPK is expressed in various primary human immune cells, with abundant 
expression in human macrophages (Hale 1999, Smith 2006). Importantly, it was 
recently shown that p38??and p38? MAPKs contribute to LPS-induced endotoxic 
shock and to collagen-induced arthritis in vivo in mice, suggesting that these p38 
isoforms have significant roles in inflammation (Risco 2012, Criado 2014). 
In addition to TLR ligands and proinflammatory cytokines, the p38 MAPKs 
are activated by various physicochemical stressors, such as UV irradiation and 
hyperosmolar shock (Cuadrado 2010). Conceivably, the p38 MAPKs could be 
activated also by the intracellular stress signals associated with NLRP3 inflammasome 
activation. In line with this reasoning, the prototypical NLRP3 activator ATP was 
reported to trigger p38 MAPK activation, though the isoform(s) were not identified 
(Donnelly-Roberts 2004, Noguchi 2008). We thus tested the hypothesis that p38 
MAPKs, and specifically the p38? MAPK, could be directly involved in triggering 
NLRP3 inflammasome assembly. 
5.2.3.2 The p38? MAPK is activated in macrophages by NLRP3 activators
We stained p38? MAPK in sections of human coronary artery plaques and found 
strong expression in intimal macrophage foam cells, as well as extracellular staining 
in the lipid core (study III, Fig. 3A and Supplemental Fig. 4A). The staining pattern 
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closely resembled that of the macrophage marker CD163 and the NLRP3 receptor 
in adjacent sections (study III, Fig. 1A and C). We subsequently studied p38 MAPK 
activation by Western blotting in cultured primary human MDMs stimulated with 
5 mM ATP to activate the NLRP3 inflammasome. Extracellular ATP triggered 
a rapid, transient phosphorylation of p38 MAPKs at 1 min of stimulation, both 
in unprimed and LPS-primed MDMs (study III, Fig. 3B). Thus, the induction of 
p38 MAPK activation was independent of cytokine signaling, and it immediately 
preceded the appearance of mature IL-1? in the culture medium of LPS-primed 
cells (study III, Fig. 3C).
We next explored the specific p38 isoforms activated during ATP stimulation. The 
p38? and p38? were the major p38 MAPK isoforms expressed in human MDMs 
(study III, Supplemental Fig. 4B). This is in agreement with earlier studies showing 
abundant p38? and p38?, but no p38? and p38? at the protein level in human 
MDMs (Hale 1999, Smith 2006). Thus, we detected the dually phosphorylated 
(Thr180/Tyr182), active forms of p38? and p38? MAPKs (p-p38? and p-p38?) 
from cell lysates by specific ELISAs. ATP triggered the activation of p38?, but 
not p38?, peaking at 1 min of stimulation (study III, Fig. 3D and Supplemental 
Fig. 4C). The ATP-induced p38? activation was dependent on the P2X7 receptor 
that mediates the ATP-triggered activation of the NLRP3 inflammasome (study 
III, Fig. 5D). Similarly, the ATP-induced phosphorylation of total p38 MAPKs is 
P2X7-dependent (Donnelly-Roberts 2004). Importantly, also cholesterol crystals 
(CHC) triggered activation of p38?, but not p38?, in unprimed and LPS-primed 
human MDMs (study III, Fig. 4A and B; Supplemental Fig. 5A and B). The p38? 
activation by CHC displayed slower kinetics that closely paralleled IL-1? secretion 
in LPS-primed cells. Thus, two structurally and functionally very different NLRP3 
activators shared the capability to activate the p38? MAPK. Moreover, ATP and 
CHC induced peak levels of p-p38? that were highly similar in magnitude to those 
induced by the canonical p38 MAPK activators, LPS and IL-1? (study III, Fig. 4C). 
Unexpectedly, we could not detect activation of p38? by LPS or IL-1? in human 
MDMs (study III, Fig. 4C), despite their well-established role in triggering p38??
activation in various cell types (Arthur 2013, Cuadrado 2010). In contrast, an earlier 
report in human MDMs showed that LPS induces the activation of both p38? and 
p38?, resulting in similar enhancements in the kinase activity of both isoforms in an 
ATF2 phosphorylation assay (Hale 1999). Despite the differing culture protocols, 
the relative expression patterns of the four p38 MAPK isoforms in human MDMs 
were highly consistent between the studies (study III, Supplemental Fig. 4B) (Hale 
1999). However, Hale et al. unexpectedly found that majority of the LPS-activated 
p-p38? was in Tyr182-monophosphorylated form (Hale 1999). Given that in 
Study III, we used ELISAs that detect only the conventional Thr180-Tyr182 dually 
phosphorylated p38? and p38?, it is possible that LPS triggered some p38? activation 
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via monophosphorylation. However, in the study by Hale et al., the antibodies against 
mono-phospho-p38 and dual-phospho-p38 were raised against a phospho-peptide 
from aa 171-186 of p38? (Hale 1999). Despite the conserved phosphorylation sites, 
the corresponding peptide sequence in p38??differs by 3 amino acids (NCBI Protein 
BLAST sequence alignment p38??NP_002745.1 vs full-length isoforms 1 and 2 of 
p38? NP_001306.1 and NP_620581.1). Thus, the failure of the dual-phospho-p38??
antibody to recognize the LPS-activated p38? could have been due to poor affinity of 
the antibody for dual-phospho-p38?, rather than due to true monophosphorylation 
(Hale 1999). To conclude, further studies are needed to account for the variable p38? 
activation by LPS observed in these two studies.  
5.2.3.3 Activation of p38? MAPK is required for NLRP3-mediated IL-1? secretion 
The available inhibitors of p38 MAPKs are restricted to a group of pyridinyl imidazole 
compounds that block p38?/?, and the newer, chemically distinct compound BIRB-
796 that blocks all four p38 isoforms (Bain 2007). We chose to use the pyridinyl 
imidazole SB203580 (SB) and BIRB-796 (BIRB), both highly specific for their p38 
MAPK targets among 80 screened kinases (Bain 2007). By using these inhibitors in 
parallel, we were able to distinguish the contribution of the two major p38 isoforms, 
p38? and p38?, in human MDMs. Thus, the p38?/??inhibitor SB will target p38?, 
whereas the p38?/?/?/? inhibitor BIRB will target both p38? and p38?. 
We showed that BIRB, but not SB, dose-dependently inhibited ATP-induced 
secretion of mature IL-1? from LPS-primed human MDMs (study III, Fig. 
5A). The inhibitors were added after LPS priming to allow unhindered synthesis 
and accumulation of pro-IL-1?. Moreover, the p38 MAPKs regulate cytokine 
transcription and translation, but not protein stability (Lee 1994, Baldassare 1999). 
Accordingly, BIRB did not affect intracellular pro-IL-1? protein levels (study III, 
Fig. 5B). The Western blots also indicated that ATP-induced secretion of pro-IL-
1? was unaffected by BIRB, suggesting that the IL-1? secretion machinery remains 
intact (study III, Fig. 5B and Supplemental Fig. 6A). Furthermore, both BIRB and 
SB were functional in human MDMs, as confirmed by inhibition of LPS-induced 
TNF-? secretion (study III, Fig. 5C). As we could not detect p38? activation by LPS 
in human MDMs, the inhibition of TNF-??secretion by SB could be mediated by 
p38?. Although much less expressed compared to p38? and p38?, the p38? mRNA 
showed a 2-fold induction by LPS priming uniquely among the p38 isoforms (study 
III, Supplemental Fig. 4B). In agreement with our data, also earlier studies failed 
to show inhibition of ATP-induced IL-1? secretion by p38?/? MAPK inhibitors 
(Donnelly-Roberts 2004, Michel 2006).
We further confirmed that BIRB, but not SB, completely inhibited the ATP-
induced p38? MAPK activation (study III, Fig. 5D). Moreover, BIRB did not affect 
the expression of NLRP3 receptor or ASC (study III, Supplemental Fig. 6C and 
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D). These data strongly suggested the involvement of p38? MAPK in activation of 
the NLRP3 inflammasome. To elucidate the activation mechanism of p38? MAPK 
during NLRP3 inflammasome activation, we blocked the intracellular stress signals 
required for NLRP3 activation. High extracellular potassium concentration, the 
general ROS inhibitor NAC, and the cathepsin B inhibitor CA-074-Me all markedly 
attenuated the peak p-p38? MAPK levels after 1 min ATP stimulation (study III, 
Fig. 6A; Supplemental Fig. 7A-D). Similarly, inhibition of potassium efflux blocked 
cholesterol crystal-induced p38? MAPK activation (study III, Fig. 6B). 
Taken together, the p38??MAPK is activated by both receptor- and phagocytosis-
dependent activators of the NLRP3 inflammasome and may integrate several 
intracellular stress signals to trigger NLRP3 inflammasome activation in human 
MDMs. The p38? MAPK was also activated during inflammasome priming and 
IL-1? signaling in human MDMs. These data suggest the involvement of p38? 
MAPK during several steps of NLRP3 inflammasome activation, revealing a novel 
proinflammatory role for this poorly characterized p38 isoform (Fig. 10). Importantly, 
the p38??MAPK and NLRP3 inflammasome components are abundantly expressed by 
macrophage foam cells surrounding the lipid cores in human coronary atherosclerotic 
Figure 10. The p38??MAPK contributes to several steps in activation of the NLRP3 
inﬂammasome in primary human macrophages. See the details in text. AP-1, activator 
protein 1; CatB, cathepsin B; IL-1RI, IL-1 receptor I; IL-1RAP, IL-1 receptor accessory protein; IKK, 
Inhibitor of ?B kinase; LPS, lipopolysaccharide; ROS, reactive oxygen species; MyD88, myeloid 
differentiation primary response 88; NF-?B, nuclear factor kappa-light-chain-enhancer of 
activated B cells; P2X7R, P2X7 receptor; TAK1, transforming growth factor ? -activated kinase; 
TLR, Toll-like receptor.
80   
plaques. These macrophages are in close contact with cholesterol crystals and with 
dying macrophages/SMCs in the lipid core, and thus frequently exposed also to 
extracellular ATP and other danger signals released upon cell death. Thus, the p38? 
MAPK-NLRP3 inflammasome signaling elicited by CHC and ATP is a relevant 
candidate pathway as a mediator of sterile inflammation in atherosclerotic lesions. 
Finally, these findings contribute new insight into the elusive activation mechanism 
of the NLRP3 inflammasome. Intriguingly, phosphorylation of ASC via a pathway 
involving spleen tyrosine kinase and c-Jun N-terminal kinases is required for ASC 
speck formation during NLRP3 inflammasome activation (Hara 2013), and the 
activation of the NLRC4 inflammasome is likewise regulated by phosphorylation 
of the NLRC4 receptor (Qu 2012). Thus, regulation by kinase signaling is emerging 
as a novel theme in inflammasome activation. 
 
5.3 THE INTERPLAY OF PRIMING AND INFLAMMASOME 
ACTIVATION IN ATHEROSCLEROTIC LESIONS                                
(II, III, UNPUBLISHED DATA)
It was recently shown that oxLDL primes the transcription of NLRP3 receptor and 
pro-IL-1? in mouse macrophages via the CD36:TLR4:TLR6 signaling complex 
(Sheedy 2013). Importantly, hypercholesterolemia in apoE-KO mice upregulates the 
NLRP3 receptor and pro-IL-1? in peritoneal macrophages and aortic wall also in 
vivo via the same complex. Moreover, oxLDL-induced crystallization of cholesterol 
in lysosomes triggers the NLRP3 inflammasome, resulting in a low level IL-1? 
response in unprimed mouse macrophages (Duewell 2010, Sheedy 2013). Indeed, 
crystallization of cholesterol, caspase-1 activation, and IL-1? immunoreactivity 
are markedly attenuated in lesions of CD36/apoE-dKO mice, accompanied by 
reduced lesion size (Sheedy 2013). Thus, a picture is emerging where LDL oxidation 
provides the priming signal, and both intracellular and extracellular CHC can 
subsequently trigger the NLRP3 inflammasome (Fig. 11). However, we could not 
detect any secretion of IL-1? by unprimed human MDMs during a prolonged 24-
48 h incubation with a high concentration (200 ?g/ml) of oxLDL (unpublished 
data). Thus, differences may exist in the responsiveness of mouse and human 
macrophages to oxLDL in the context of inflammasome priming and activation. 
Interestingly, recent studies at our research group (Satu Lehti and Katariina Öörni, 
unpublished results) and by our collaborators (Estruch 2015) suggest that primary 
human monocytes and macrophages respond more strongly to other types of LDL 
modification. In addition, atherosclerotic lesions harbour several microbial and 
endogenous TLR ligands that may contribute to the inflammasome priming step 
(Zimmer 2015).
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Cholesterol crystals (CHC) and oxLDL are the prominent, lipid-derived danger 
signals in atherosclerotic plaques. They coexist in the lesions with several other 
activators of the NLRP3 inflammasome, including extracellular acidosis (study II), 
ATP (Mariathasan 2006), the acute phase protein serum amyloid A (SAA) (Niemi 
2011), activated complement (Laudisi 2013), and certain components released 
from the extracellular matrix (Babelova 2009, Yamasaki 2009). Various modes of 
interaction can be envisioned between these dangers signals, yet the area remains 
largely unexplored. Samstad et al. reported complement activation by CHC in 
whole blood (Samstad 2014). The subsequent CHC opsonisation by complement 
augments CHC phagocytosis and inflammasome activation in human monocytes, 
revealing a bidirectional interaction between these signals. We explored the effects 
of acidic environment on NLRP3 inflammasome activation by CHC and SAA. The 
mildly acidic environment of pH 7.0 triggered a modest IL-1? response in THP-1 
macrophages (study II, Fig. 1B and D). However, when we treated the cells with CHC 
and SAA at pH 7.0, we found significant synergy between these signals, as indicated 
by the amplified IL-1? response (study II, Fig. 6A and B). Thus, local acidosis may 
Figure 11. The interplay between priming and activation of the NLRP3 inﬂammasome 
in atherosclerotic plaques. See the text for details. AP-1, activator protein 1; CD, cluster of 
differentiation; NF-?B, nuclear factor kappa-light-chain-enhancer of activated B cells; oxLDL, 
oxidized low density lipoprotein; P2X7R, P2X7 receptor; SAA, serum amyloid A; TLR, Toll-like 
receptor.
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substantially potentiate NLRP3 inflammasome activation by other danger signals 
by creating a sensitizing microenvironment for macrophages (Fig. 11).  
Conversely, antagonism may also occur between the NLRP3-activating danger 
signals. Acidosis likely attenuates ATP-induced inflammasome activation, owing to 
the severe inhibition of ATP-induced P2X7 receptor ion currents at low pH (Liu 
2009). However, SAA triggers NLRP3 activation via the P2X7 receptor at neutral 
pH (Niemi 2011), which is at odds with the observed synergy demonstrated between 
low pH and SAA in triggering IL-1??secretion (study II, Fig. 6B). The exact mode of 
interaction between SAA and the P2X7 receptor is not known and it is possible that 
this interaction is pH-independent. Moreover, SAA interacts with several receptors, 
including the SR CD36 that mediates cellular uptake of SAA (Baranova 2010). 
CD36 acts as a receptor also for oxLDL and amyloid-?? and is involved in the 
transformation of these ligands in lysosomes into NLRP3-activating crystals and 
fibrils, respectively (Sheedy 2013). Similarly, SAA is transformed into pathological 
fibrillar aggregates upon endocytosis by human monocytes (Magy 2007). Thus, 
hypothetically, SAA could activate the NLRP3 inflammasome via an alternative 
CD36-mediated pathway at low pH.    
During our studies on acidic pH, we became likewise interested in the effects 
of alkaline pH. Unexpectedly, the deviation from physiological pH towards more 
alkaline values did not trigger NLRP3 inflammasome activation, but rather blocked 
it (study II, Fig. 7). The IL-1? response to monosodium urate crystals, SAA, and 
CHC was sharply reduced at pH 8.0-8.5, especially in THP-1 macrophages 
(study II, Fig. 7A-C and E). The interaction of SAA with TLRs was unaffected by 
alkaline environment (study II, Fig. 7D). Similarly, phagocytosis of CHC was not 
blocked at pH 8.0 and the expression of NLRP3, ASC, and pro-IL-1? remained 
unchanged in alkaline environment (study II, Fig. 7F and Supplemental Fig. S6C). 
Interestingly, the lipid-rich areas of human carotid plaques tend to be acidified, 
whereas extensively calcified areas exhibit marked alkalinisation (Naghavi 2002). This 
type of macrocalcification stabilizes atherosclerotic plaques by reducing inflammation, 
and inhibition of NLRP3 inflammasome activity by alkaline calcium salts could 
conceivably contribute to this process (Naghavi 2002, Pugliese 2015). In line with 
this reasoning, NLRP3 immunoreactivity was absent in fibrocalcific lesions with low 
numbers of macrophages and large calcific cores (study III, Supplemental Fig. 2D). 
On the other hand, microcalcification is associated with inflamed plaques, implying 
differing roles for calcification depending on the calcification mechanism (Pugliese 
2015).
The activation of the NLRP3 inflammasome may shape the local immune response 
in the plaques via several mechanisms. We found significant upregulation of CIITA, 
a regulatory protein essential for class II HLA molecule expression, in advanced 
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coronary plaques compared to early lesions (study III, Table 1) (Steimle 1993, Steimle 
1994). As CIITA is an NLR family protein, we became interested in the possible 
connection between antigen presentation and NLRP3 inflammasome activation. We 
found strong downregulation of CIITA mRNA by CHC and low pH in human 
MDMs, independently of the inflammasome-mediated cytokine response (study 
III, Fig. 2A and B). This was reflected in significant downregulation of HLA-DRA 
and HLA-DRB expression by CHC (study III, Fig. 2C and D). Interestingly, CHC 
could suppress CIITA via p38 MAPK activation, as p38 MAPK contributed to 
the inhibition of IFN-?-inducible class II HLA expression by LPS (Yao 2006). 
Surprisingly, CHC and low pH downregulated also NLRP3 receptor mRNA in 
unprimed, but not in LPS-primed MDMs (study III, Supplemental Fig. 3A). These 
observations highlight the strict regulation of NLRP3-mediated sterile inflammatory 
responses in macrophages. Firstly, endogenous activators of NLRP3 suppress receptor 
expression in the absence of an appropriate priming stimulus. Secondly, when both 
priming and inflammasome activation occur, the coupling of this innate immune 
response to adaptive immunity may be weakened due to attenuated expression of 
CIITA and HLA class II antigen-presenting molecules.   
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6 CONCLUSIONS & FUTURE PERSPECTIVES
This thesis focused on studying the mechanisms that drive inflammation during 
atherogenesis. Despite the well-established role of inflammation in atherosclerotic 
plaque development, there are currently no treatment strategies for atherosclerosis 
and cardiovascular disease (CVD) that would directly target the inflammatory 
process. Nevertheless, statins have both LDL-lowering and anti-inflammatory 
effects, although the existence of direct anti-inflammatory effects remains debated 
(Bonetti 2003, Shaw 2009). A large prospective cohort study demonstrated that 
reduction of high-sensitivity C-reactive protein (hsCRP) levels by rosuvastatin 
treatment significantly reduced cardiovascular event rates even in apparently healthy 
people with low LDL cholesterol (Ridker 2009). This landmark study provided 
persuasive evidence supporting a key role for inflammation in the pathogenesis 
of atherosclerosis, independent of LDL cholesterol levels. Furthermore, the study 
sparked a wide interest towards finding a more targeted anti-inflammatory therapy 
for the treatment of atherosclerosis and CVD (Ridker 2014). 
In order to develop novel anti-inflammatory treatment strategies, a detailed 
mechanistic understanding of the immunopathogenesis of atherosclerosis is vital 
(Libby 2015, Libby 2011). Innate immunity has an essential role in atherogenesis 
through the intimate involvement of macrophages both in lipid accumulation and 
inflammation in the arterial wall. This thesis explored a major innate immune signaling 
pathway, the inflammasome, in the context of atherosclerosis. We characterized two 
novel atherosclerosis-associated activators of the inflammasome pathway, cholesterol 
crystals and local extracellular acidosis, that elicited a strong inflammatory response 
in cultured human macrophages (studies I and II). These endogenous danger signals 
activated the NLRP3 inflammasome that is now widely implicated as a mediator of 
sterile inflammation in metabolic diseases (Robbins 2014). Once formed, cholesterol 
crystals are highly persistent in atherosclerotic lesions and thus a good candidate as a 
mediator of chronic inflammation. Moreover, even a very mildly acidified environment 
sensitized the macrophages to cholesterol crystals and other NLRP3 activators, 
implying a general role in amplification of NLRP3-mediated inflammation. 
In Study III, we performed a comprehensive analysis of inflammasome pathway-
related gene expression in human coronary artery samples. A signature of three 
inflammasome core components – ASC, caspase-1, and IL-18 – was consistently 
upregulated in advanced atherosclerotic plaques compared to early lesions from the 
same coronary trees. Moreover, we found upregulation of p38? MAPK, a poorly 
characterized isoform of the stress- and cytokine-activated p38 MAPK family, in 
advanced coronary plaques when compared to early lesions. Immunohistochemical 
stainings showed that the p38? MAPK localized in lesional macrophage foam cells 
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together with NLRP3, ASC, and caspase-1. In a series of experiments in cultured 
human macrophages, we identified the p38? MAPK as a novel mediator of NLRP3 
inflammasome activation by cholesterol crystals and ATP. Taken together, the studies 
presented in this thesis revealed the existence of potent endogenous triggers of 
the NLRP3 inflammasome and IL-1?/IL-18 secretion in atherosclerotic lesions, 
and identified the p38? MAPK as a novel effector in NLRP3-mediated sterile 
inflammation. 
Cholesterol crystals were dismissed for decades as an inert, terminal form of 
cholesterol accumulation in the arterial wall. Results by our group (study I) and by 
Duewell et al. (Duewell 2010) challenged this view by showing that rather than an end 
point, the crystallization of cholesterol represents a transformation of this lipid into 
a proinflammatory danger signal. Moreover, Duewell et al. revealed the appearance 
of cholesterol microcrystals already at the earliest stages of lesion development in 
mouse aortic wall (Duewell 2010). Similarly, small cholesterol crystals occur already 
in human fatty streaks, yet a sharp increase in free cholesterol and cholesterol crystals 
is observed upon transition from the clinically silent type III lesion to the potentially 
symptomatic type IV lesion (Stary 1995, Small 1988). Thus, a critical concentration 
of free cholesterol may tip the balance strongly towards crystal nucleation and drive 
the transition of the lesion from a benign stage to a pathological one. Supporting 
this notion, clinical trials with inhibitors of the acyl–coenzyme A:cholesterol 
acyltransferase (ACAT) showed accelerated coronary and carotid atherosclerosis, 
as well as increased cardiovascular event rates (Nissen 2006, Meuwese 2009). The 
ACAT inhibitors block esterification of cellular cholesterol, the hallmark of foam 
cell formation. Thus, the data suggest an overall cardioprotective effect for cholesterol 
esterification, and, conversely, a pathogenic role for accumulation of free cholesterol 
that promotes crystal nucleation. 
Along these lines, drugs that could inhibit cholesterol crystallization or dissolve 
cholesterol crystals from the arterial wall could be beneficial in reducing arterial wall 
inflammation and atherosclerotic plaque development. A promising candidate drug 
is 2-hydroxypropyl-?-cyclodextrin that redirects excess cholesterol from lysosomes 
into the cytoplasm for esterification and thus reduces lysosomal crystallization of 
cholesterol (Walenbergh 2015). Administration of this drug to LDLR-KO mice 
on high-fat diet decreased lysosomal cholesterol accumulation and crystallization 
in liver Kupffer cells (specialized macrophages), while increasing the amount of 
cytoplasmic cholesterol ester droplets (Walenbergh 2015). Further studies are needed 
to elucidate the mechanism of action behind these effects and to determine whether 
2-hydroxypropyl-?-cyclodextrin has similar effects in macrophage foam cells of 
atherosclerotic plaques. 
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The p38 MAPKs, and p38? in particular, have been linked to various stages 
of cardiovascular pathology in a plethora of studies in cultured cells and animal 
models (Martin 2015). Of note, these studies were focused almost exclusively on the 
p38? and p38??????????, while p38? and p38? remain unexplored. The activation 
of p38?/? has been associated with endothelial dysfunction, atherosclerosis, platelet 
activation, thrombosis, ischemic heart injury, and with pathological post-infarction 
remodeling and fibrosis in the heart (Martin 2015). These observations have led to 
clinical trials with the p38?/? inhibitor losmapimod that was shown to significantly 
improve vascular function of atherosclerotic patients after 1-3 months of  treatment 
(Cheriyan 2011, Elkhawad 2012). Thus, losmapimod improved endothelial function 
and reduced both systemic inflammation (hsCRP) and local inflammatory activity 
in atherosclerotic segments of carotids and aorta. Encouraged by these results, a 
large phase III clinical trial exploring the effect of losmapimod on cardiovascular 
outcomes in patients with acute coronary syndrome (the LATITUDE-TIMI 60 trial) 
was initiated in 2014, with an aim to recruit > 20 000 patients (O’Donoghue 2015). 
Despite these promising developments, there are some concerns related to 
targeting the p38 MAPK pathway for suppressing atherosclerotic inflammation. The 
primary target of drug development, p38? MAPK, promotoes the development of 
ischemic heart injury but is also required for the cardioprotective effects of ischemic 
preconditioning (Sicard 2010, Kumphune 2010). Moreover, endothelium- or 
macrophage-specific knock-out of p38? had no effects, or even aggravating effects 
on atherogenesis in mouse models (Kardakaris 2011, Seimon 2009). Lastly, clinical 
studies with inhibitors targeting p38? in rheumatoid arthritis have faced problems 
with adverse effects, perhaps related to the diverse functions of this ubiquitous isoform 
(Genovese 2009). The p38? MAPK is essential for embryonal development in mice, 
whereas knock-out animals of the other p38 isoforms are fully viable and fertile 
(Cuenda 2007). Taken together, p38 isoforms beyond p38?, including the p38??
MAPK associated with inflammasome activation, may offer alternative targets for 
the anti-inflammatory treatment of CVD.
The value of hsCRP in cardiovascular risk prediction has been validated in 
numerous prospective studies in human populations, yet it is considered mainly a 
marker rather than a causal agent in CVD (Koenig 2013). As a more direct measure 
of ongoing inflammatory signaling, the plasma levels of certain proinflammatory 
cytokines, including IL-6 and IL-18, have been identified as independent predictors 
of cardiovascular risk (Ridker 2000, Blankenberg 2002, IL6R Genetics Consortium 
Emerging Risk Factors Collaboration 2012, Kaptoge 2014). Indeed, targeting of 
specific key proinflammatory cytokines has emerged as a potential therapeutic 
strategy to reduce cardiovascular events (Ridker 2014). 
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Notably, IL-1? was recently chosen as the target cytokine in a large phase III 
clinical trial exploring cardiovascular outcomes, the Canakinumab Anti-inflammatory 
Thrombosis Outcomes Study (CANTOS) (Ridker 2011). The decision was based on 
the growing body of evidence linking the balance between IL-1 and IL-1Ra with 
the pathogenesis of atherosclerosis and CVD (Ridker 2011). Notably, IL-1? is also 
a highly potent inducer of IL-6 in vivo, and strategies blocking IL-1 signaling are 
effective in reducing the systemic levels of IL-6 (Dinarello 2009). The drug under 
evaluation in CANTOS is a monoclonal IL-1?-neutralizing antibody, canakinumab, 
previously approved for the treatment of e.g. autoinflammatory syndromes. The 
CANTOS study enrolled a total of 10 065 post-myocardial infarction patients 
with persistent elevation of hsCRP to evaluate the efficacy of anti-inflammatory 
treatment on recurrent cardiovascular events (enrollment data by trial chairman, 
Dr. Paul M. Ridker, at the 12th World Congress on Inflammation, August 2015, 
Boston, Massachusetts, USA). A smaller pilot study of CANTOS has already been 
published, demonstrating efficient lowering of hsCRP and IL-6 by canakinumab 
in the absence of major effects on blood lipids (Ridker 2012). The results of the 
CANTOS study (estimated completion 2017) are eagerly awaited, as this is the 
first large-scale outcome trial directly assessing the inflammatory hypothesis of 
atherosclerosis and atherothrombosis. 
Beyond blocking cytokine signaling, there is a growing interest towards developing 
drugs that block the activity of the inflammasome pathway. Several small-molecule 
drugs have been shown to inhibit inflammasome activation. The first compound 
identified was the type II diabetes drug glyburide that blocks the activation of the 
NLRP3 inflammasome, but not NLRP1 or NLRC4 inflammasomes (Lamkanfi 
2009). The NF-?B inhibitory drugs parthenolide and Bay 11-7082 function by 
inactivating caspase-1 by alkylation and by blocking the ATPase activity of the NLRP3 
receptor, respectively ( Juliana 2010). Moreover, Coll et al. reported a compound that 
interferes with the oligomerization of ASC and thus blocks the activation of the 
ASC-dependent NLRP3 and AIM2 inflammasomes at micromolar concentrations 
(Coll 2011). In 2015, the same group reported another, much more potent compound, 
MCC950, that selectively inhibits NLRP3 inflammasome activation at nanomolar 
concentrations, without affecting the activation of NLRP1, NLRC4, and AIM2 
inflammasomes (Coll 2015). Importantly, MCC950 was active in vivo in mouse 
models of multiple sclerosis and CAPS, and ex vivo in monocytes of CAPS patients 
(Coll 2015). 
Although the above-mentioned compounds have not yet been tested in the context 
of atherosclerosis, a plant-derived compound called arglabin was recently shown 
to attenuate atherogenesis in mice via inhibition of the NLRP3 inflammasome 
(Abderrazak 2015). The suggested mechanism of action was an indirect inhibition 
of NLRP3 inflammasome activity via enhancement of autophagy, yet arglabin 
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also markedly reduced the levels of total cholesterol and triglycerides in plasma. 
This first demonstration of the beneficial effects of NLRP3-blocking drugs in 
atherosclerosis will no doubt encourage further studies with other inflammasome 
inhibitors under development. Indeed, the interest in the inflammasome pathway 
as a mediator of inflammation in atherosclerosis has rapidly expanded since the first 
reports on cholesterol crystal-mediated NLRP3 activation. Importantly, the NLRP3 
inflammasome contributes not only to inflammation in atherosclerotic plaques, 
but also mediates obesity-induced inflammation in the adipose tissue and liver, 
and thus contributes to the development of insulin resistance and type II diabetes 
(Vandanmagsar 2011, Stienstra 2011). As obesity and type II diabetes are major risk 
factors for the development of atherosclerosis and CVD, the NLRP3 inflammasome 
is a compelling therapeutic target in the treatment of these closely linked metabolic 
disorders that represent a major global health threat. 
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